U.S. patent application number 14/740598 was filed with the patent office on 2015-12-10 for substituted oxindole derivatives and their use as vasopressin receptor ligands.
The applicant listed for this patent is ABBVIE DEUTSCHLAND GMBH & CO. KG. Invention is credited to Wilfried Braje, Herve Geneste, Wilfried Hornberger, Wilfried Lubisch, Astrid Netz, Thorsten Oost, Liliane Unger, Wolfgang Wernet (Deceased).
Application Number | 20150352110 14/740598 |
Document ID | / |
Family ID | 39125247 |
Filed Date | 2015-12-10 |
United States Patent
Application |
20150352110 |
Kind Code |
A1 |
Netz; Astrid ; et
al. |
December 10, 2015 |
SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN
RECEPTOR LIGANDS
Abstract
The present invention relates to novel oxindole derivatives of
the general formula (I) to medicaments comprising them and to their
use for the prophylaxis and/or treatment of diseases vasopressin
dependent. ##STR00001##
Inventors: |
Netz; Astrid; (Ludwigshafen,
DE) ; Oost; Thorsten; (Biberach an der Riss, DE)
; Geneste; Herve; (Ludwigshafen, DE) ; Braje;
Wilfried; (Ludwigshafen, DE) ; Wernet (Deceased);
Wolfgang; (Ludwigshafen, DE) ; Unger; Liliane;
(Ludwigshafen, DE) ; Hornberger; Wilfried;
(Ludwigshafen, DE) ; Lubisch; Wilfried;
(Heidelberg, DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ABBVIE DEUTSCHLAND GMBH & CO. KG |
Wiesbaden |
|
DE |
|
|
Family ID: |
39125247 |
Appl. No.: |
14/740598 |
Filed: |
June 16, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14481847 |
Sep 9, 2014 |
|
|
|
14740598 |
|
|
|
|
13590261 |
Aug 21, 2012 |
8859557 |
|
|
14481847 |
|
|
|
|
12521713 |
Sep 7, 2010 |
8815868 |
|
|
PCT/EP2007/064622 |
Dec 28, 2007 |
|
|
|
13590261 |
|
|
|
|
Current U.S.
Class: |
514/253.09 ;
514/316 |
Current CPC
Class: |
A61K 31/506 20130101;
A61P 25/28 20180101; A61P 3/00 20180101; A61P 25/20 20180101; A61P
1/04 20180101; A61P 9/00 20180101; A61K 31/4545 20130101; A61P 7/02
20180101; A61P 1/08 20180101; A61P 25/18 20180101; A61P 25/00
20180101; C07D 401/14 20130101; A61P 7/00 20180101; A61P 9/12
20180101; A61P 1/00 20180101; A61P 9/10 20180101; A61P 25/24
20180101; A61P 13/12 20180101; A61P 25/22 20180101; A61P 1/16
20180101; A61P 13/00 20180101; A61P 3/10 20180101; A61P 25/30
20180101 |
International
Class: |
A61K 31/506 20060101
A61K031/506; A61K 31/4545 20060101 A61K031/4545 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 30, 2006 |
DE |
102006062505.6 |
Dec 30, 2006 |
DE |
102006062506.4 |
Dec 30, 2006 |
DE |
102006062507.2 |
Dec 30, 2006 |
DE |
102006062508.0 |
Claims
1.-51. (canceled)
52. A method for the treatment of at least one disorder selected
from the group consisting of diabetes, insulin resistance,
nocturnal enuresis, incontinence, diseases in which blood
coagulation disorders occur, hypertension, pulmonary hypertension,
heart failure, myocardial infarction, coronary spasm, unstable
angina, PTCA (percutaneous transluminal coronary angioplasty),
ischemias of the heart, disorders of the renal system, edemas,
renal vasospasm, necrosis of the renal cortex, hyponatremia,
hypokalemia, Schwartz-Bartter syndrome, disorders of the
gastrointestinal tract, gastritic vasospasm, hepatocirrhosis,
gastric and intestinal ulcer, emesis, emesis occurring during
chemotherapy, travel sickness, affective disorders, memory
impairments and/or Alzheimer's disease, psychoses and/or psychotic
disorders, Cushing's syndrome, sleep disorders, vasomotor symptoms
and/or thermoregulatory dysfunctions, drug dependencies, medicament
dependencies and/or dependencies mediated by other factors, stress
caused by the withdrawal of one or more factors mediating the
dependency, stress-induced relapses in the drug dependencies,
medicament dependencies and/or dependencies mediated by other
factors, schizophrenia and/or psychosis, or for delaying
micturition in a patient, characterized in that an effective amount
of at least one compound of the general formula (I) or at least one
pharmaceutically acceptable salt, or one tautomeric form thereof,
is administered to a patient in need thereof, ##STR00008## in which
R1 is ethoxy; R2 is hydrogen; R3 is cyano; R4 is hydrogen; R5 is
hydrogen, methoxy or ethoxy; R6 is hydrogen or methoxy; R7 is
hydrogen, methyl, ethyl, n-propyl or isopropyl; X1 is --NH--; X2 is
N or CH; and X3 is N or CH; where X2 and X3 are not simultaneously
N.
53. The method according to claim 52, in which R5 is hydrogen or
methoxy.
54. The method according to claim 52, in which R7 is hydrogen,
methyl or ethyl.
55. The method according to claim 52, in which R5 is hydrogen or
methoxy; R7 is hydrogen, methyl or ethyl; X1 is --NH--; X2 is N;
and X3 is CH.
56. The method according to claim 52, in which R5 is hydrogen or
methoxy; R7 is hydrogen, methyl or ethyl; X1 is --NH--; X2 is CH;
and X3 is N.
57. The method according to claim 52, in which R5 is methoxy; R6 is
methoxy; R7 is methyl or ethyl; X1 is --NH--; and X2 is CH and X3
is N or X2 is N and X3 is CH.
58. The method according to claim 52, in which R5 is methoxy; R6 is
methoxy; R7 is methyl; X1 is --NH--; X2 is N; and X3 is CH.
59. The method according to claim 52, in which R5 is methoxy; R6 is
methoxy; R7 is methyl; X1 is --NH--; X2 is CH; and X3 is N.
60. The method according to claim 52, in which R5 is methoxy; R6 is
methoxy; R7 is ethyl; X1 is --NH--; X2 is CH; and X3 is N.
61. The method according to claim 52, wherein the compound of the
general formula (I), or a pharmaceutically acceptable salt thereof,
or a tautomeric form thereof, is present in optically active form
as the (laevorotatory) (-)-enantiomer, which rotates the plane of
polarization of linear polarized light to the left.
62. The method according to claim 52, wherein the compound of the
general formula (I) has formula (Ia), ##STR00009## wherein the
absolute configuration of the chiral C-3 ring carbon atom
corresponds to the absolute configuration at C-3 of the
(laevorotatory) (-)-enantiomer, which rotates the plane of
polarization of linear polarized light to the left, a
pharmaceutically acceptable salt thereof, or a tautomeric form
thereof.
63. The method according to claim 61, characterized in that the
corresponding laevorotatory (-)-enantiomer is present in an optical
purity (enantiomeric excess, ee) of greater than 50%, a
pharmaceutically acceptable salt thereof, or a tautomeric form
thereof.
64. The method according to claim 62, characterized in that the
enantiomer having the preferred absolute configuration at the C-3
ring carbon atom is present in an optical purity (enantiomeric
excess, ee) of greater than 50%, a pharmaceutically acceptable salt
thereof, or a tautomeric form thereof.
65. The method according to claim 61, characterized in that the
corresponding laevorotatory (-)-enantiomer is present in an optical
purity (enantiomeric excess, ee) of greater than 90%, a
pharmaceutically acceptable salt thereof, or a tautomeric form
thereof.
66. The method according to claim 62, characterized in that the
enantiomer having the preferred absolute configuration at the C-3
ring carbon atom is present in an optical purity (enantiomeric
excess, ee) of greater than 90%, a pharmaceutically acceptable salt
thereof, or a tautomeric form thereof.
67. The method according to claim 52, wherein the compound of the
general formula (I) is in the form of the racemate, a
pharmaceutically acceptable salt thereof, or a tautomeric form
thereof.
68. The method according to claim 52, characterized in that an
effective amount of at least one medicament comprising at least one
compound of the general formula (I), or at least one
pharmaceutically acceptable salt, or one tautomeric form thereof,
is administered to the patient.
69. The method according to claim 52, characterized in that the
patient is a mammal.
Description
[0001] The present invention relates to novel substituted oxindole
derivatives, to medicaments comprising them and to their use for
treating diseases.
[0002] Vasopressin is an endogenous hormone which exerts widely
diverse effects on organs and tissues. It is suspected that the
vasopressin system is involved in various pathological states such
as, for example, heart failure and high blood pressure. At present
three receptors (V1a, V1b or V3 and V2) via which vasopressin
mediates its numerous effects are known. Antagonists of these
receptors are therefore being investigated as possible novel
therapeutic approaches to the treatment of diseases (M. Thibonnier,
Exp. Opin. Invest. Drugs 1998, 7(5), 729-740).
[0003] The present application describes novel substituted
oxindoles carrying an arylsulphonyl group in position 1.
1-Phenylsulphonyl-1,3-dihydro-2H-indol -2-ones have previously been
described as ligands of vasopressin receptors. WO 93/15051,
WO95/18105, WO 98/25901, WO 01/55130, WO 01/55134, WO 01/64668 and
WO 01/98295 describe derivatives derived from the oxindole skeleton
and having arylsulphonyl groups in position 1. These compounds
differ essentially in the substitution in position 3.
[0004] In particular, WO 93/15051 and WO 98/25901 describe
1-phenylsulphonyl-1,3-dihydro-2H-indol-2-ones in which the oxindole
structure is substituted in position 3 by two alkyl radicals which
may also together form a cycloalkyl radical (spiro linkage) as
ligands of vasopressin receptors. Alternatively, the spiro ring may
comprise heteroatoms, such as oxygen and nitrogen (optionally with
substituents).
[0005] WO 95/18105 describes 1-phenylsulphonyl-1,3-dihydro-2H-indol
-2-ones having a nitrogen atom in position 3 as ligands of
vasopressin receptors. In addition, radicals which are selected
from the group consisting of alkyl, cycloalkyl, phenyl and benzyl
are attached in position 3 (in each case optionally with
substituents).
[0006] WO 03/008407 describes 1-phenylsulphonyloxindoles in which
pyridylpiperazines are attached via an oxycarbonyl group to the
oxindole in position 3.
[0007] WO 2005/030755 describes as Example 108, the carbamate
compound 4-(1-methylpiperidin-4-yl)piperazine-1-carboxylic acid
5-cyano-1-(2,4-dimethoxy-phenylsulphonyl)-3-(2-methoxypyridin-3-yl)-2-oxo-
-2,3-dihydro-1H-indol-3-yl ester (according to IUPAC nomenclature:
5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-methoxypyridin-3-yl)-2-ox-
o-2,3-dihydro-1H-indol-3-yl4-(1-methylpiperidin-4-yl)piperazine-1-carboxyl-
ate).
[0008] WO 06/005609 describes the 2-ethoxyphenyl urea compounds
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxyphenyl)-2-oxo-2,-
3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carboxamid-
e (as Example 119) and
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxyphenyl)-2-oxo-2,-
3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carboxamid-
e (as Example 128).
[0009] In addition to the binding affinity to the vasopressin V1b
receptor, further properties may be advantageous in the treatment
and/or prophylaxis of vasopressin-dependent disorders, such as, for
example:
[0010] 1.) a selectivity for the vasopressin V1b receptor over the
vasopressin V1a receptor, i.e. the quotient of the binding affinity
to the V1a receptor (Ki(V1a) (determined in the unit "nanomolar
(nM)") and the binding affinity to the V1b receptor (Ki(V1b))
(determined in the unit "nanomolar (nM)"). The greater the quotient
Ki(V1a)/Ki(V1b), the greater the V1b selectivity;
[0011] 2.) a selectivity for the vasopressin V1b receptor over the
vasopressin V2 receptor, i.e. the quotient of the binding affinity
to the V2 receptor (Ki(V2) (determined in the unit "nanomolar
(nM)") and the binding affinity to the V1b receptor (Ki(V1b))
(determined in the unit "nanomolar (nM)"). The greater the quotient
Ki(V2)/Ki(V1b), the greater the V1b selectivity;
[0012] 3.) a selectivity for the vasopressin V1b receptor over the
oxytocin OT receptor, i.e. the quotient of the binding affinity to
the OT receptor (Ki(OT) (determined in the unit "nanomolar (nM)")
and the binding affinity to the V1b receptor (Ki(V1b)) (determined
in the unit "nanomolar (nM)"). The greater the quotient
Ki(OT)/Ki(V1b), the greater the V1b selectivity;
[0013] 4.) the metabolic stability, determined, for example, using
the half-life determined in vitro in liver microsomes of various
species (for example rat or human);
[0014] 5.) only minor, if any, inhibition of cytochrom P450 (CYP)
enzymes: cytochrom P450 (CYP) is the name for a superfamily of haem
proteins having enzymatic activity (oxidases). They are also of
particular importance for the degradation (metabolism) of foreign
substances, such as pharmaceutics or xenobiotics, in mammalian
organisms. The most important representatives of the types and
subtypes of CYP in the human organism are: CYP 1A2, CYP 2C9, CYP
2D6 and CYP 3A4. When CYP 3A4 inhibitors (for example grapefruit
juice, cimetidine, erythromycin) and medicaments which are degraded
via this enzyme system and which thus compete for the same binding
site at the enzyme are administered simultaneously, their
degradation may be slowed down, and actions and side-effects of the
medicament administered may be enhanced in an unwanted manner;
[0015] 6.) suitable solubility in water (in mg/ml);
[0016] 7.) suitable pharmacokinetics (temporal profile of the
concentration of the compound according to the invention in the
plasma or in tissues, for example brain). Pharmacokinetics may be
described by the following parameters: half-life, distribution
volume, plasma clearance, AUC ("area under the curve", area under
the concentration-time curve), oral bioavailability, the
brain/plasma ratio;
[0017] 8.) a certain proportion of the active substance is present
attached to plasma proteins (drug/plasma protein binding (PPB)
value);
[0018] 9.) no or only minor blockage of the hERG channel: compounds
which block the hERG channel may prolong the QT interval, thus
leading to serious irregularities of pulse (for example "torsade de
pointes"). Using a displacement assay described in the literature
with radioactively labelled dofetilide (G. J. Diaz et al., Journal
of Pharmacological and Toxicological Methods, 50 (2004), 187-199),
it is possible to determine the potential of compounds of blocking
the hERG channels. The lower the IC50 in this "dofetilide assay",
the more likely a potent hERG blockage. In addition, the blockage
of the hERG channel may be measured by electrophysical experiments
using cells transfected with the hERG channel, by "whole-cell patch
clamping" (G. J. Diaz et al., Journal of Pharmacological and
Toxicological Methods, 50 (2004), 187-199).
[0019] It is an object of the present invention to provide a
compound with high and selective activity, preferably in particular
for the vasopressin V1b receptor, for the treatment or prophylaxis
of various vasopressin-dependent diseases. In addition, the
substance according to the invention should have one or more of the
advantages 1.) to 9.) mentioned above, in particular a suitable
selectivity for the V1b receptor over the V1a receptor.
[0020] This object is achieved by compounds of the general formula
(I)
##STR00002##
[0021] in which [0022] R1 is ethoxy; [0023] R2 is hydrogen; [0024]
R3 is cyano; [0025] R4 is hydrogen; [0026] R5 is hydrogen, methoxy
or ethoxy; [0027] R6 is hydrogen or methoxy; [0028] R7 is hydrogen,
methyl, ethyl, n-propyl or isopropyl; [0029] X1 is --NH--; [0030]
X2 is N or CH; [0031] X3 is N or CH;
[0032] where X2 and X3 are not simultaneously N (that is to say are
a nitrogen atom); and by the pharmaceutically acceptable salts,
tautomeric forms, and prodrugs thereof.
[0033] Accordingly, the present invention relates to compounds of
the general formula (I) (also "compounds (I)" below), including the
tautomeric forms thereof, and the pharmaceutically acceptable salts
of the compounds (I) and the prodrugs of the compounds (I).
[0034] A preferred subject-matter of the invention are compounds of
the general formula (I) in which
[0035] R1 is ethoxy;
[0036] R2 is hydrogen;
[0037] R3 is cyano;
[0038] R4 is hydrogen;
[0039] R5 is hydrogen or methoxy, in particular methoxy;
[0040] R6 is hydrogen or methoxy, in particular methoxy;
[0041] R7 is hydrogen, methyl, ethyl, n-propyl or isopropyl;
[0042] X1 is --NH--;
[0043] X2 is N or CH;
[0044] X3 is N or CH;
[0045] where X2 and X3 are not simultaneously a nitrogen atom;
[0046] and the pharmaceutically acceptable salts, tautomeric forms,
and prodrugs thereof.
[0047] A particularly preferred subject-matter of the invention are
compounds of the general formula (I) in which
[0048] R1 is ethoxy;
[0049] R2 is hydrogen;
[0050] R3 is cyano;
[0051] R4 is hydrogen;
[0052] R5 is hydrogen or methoxy, in particular methoxy;
[0053] R6 is hydrogen or methoxy, in particular methoxy, in
particular methyl or ethyl;
[0054] R7 is hydrogen, methyl or ethyl;
[0055] X1 is --NH--;
[0056] X2 is N;
[0057] X3 is CH;
[0058] and the pharmaceutically acceptable salts, tautomeric forms,
and prodrugs thereof.
[0059] A further particularly preferred subject-matter of the
invention are compounds of the general formula (I) in which
[0060] R1 is ethoxy;
[0061] R2 is hydrogen;
[0062] R3 is cyano;
[0063] R4 is hydrogen;
[0064] R5 is hydrogen or methoxy, in particular methoxy;
[0065] R6 is hydrogen or methoxy, in particular methoxy;
[0066] R7 is hydrogen, methyl or ethyl, in particular methyl or
ethyl;
[0067] X1 is --NH--;
[0068] X2 is CH;
[0069] X3 is N;
[0070] and the pharmaceutically acceptable salts, tautomeric forms,
and prodrugs thereof.
[0071] A further particularly preferred subject-matter of the
invention are compounds of the general formula (I) in which
[0072] R1 is ethoxy;
[0073] R2 is hydrogen;
[0074] R3 is cyano;
[0075] R4 is hydrogen;
[0076] R5 is hydrogen or methoxy, in particular methoxy;
[0077] R6 is hydrogen or methoxy, in particular methoxy;
[0078] R7 is hydrogen, methyl or ethyl, in particular methyl or
ethyl;
[0079] X1 is --NH--;
[0080] X2 is CH;
[0081] X3 is CH;
[0082] and the pharmaceutically acceptable salts, tautomeric forms,
and prodrugs thereof.
[0083] A further particularly preferred subject-matter of the
invention are compounds of the general formula (I) in which
[0084] R1 is ethoxy;
[0085] R2 is hydrogen;
[0086] R3 is cyano;
[0087] R4 is hydrogen;
[0088] R5 is methoxy;
[0089] R6 is methoxy;
[0090] R7 is methyl or ethyl;
[0091] X1 is --NH--;
[0092] X2 is CH and X3 is N; or
[0093] X2 is N and X3 is CH;
[0094] and the pharmaceutically acceptable salts, tautomeric forms,
and prodrugs thereof.
[0095] Examples of preferred embodiments of the present invention
are compounds according to the general formula (I), and the
pharmaceutically acceptable salts, tautomeric forms, and prodrugs
thereof, in which
[0096] R1 is ethoxy,
[0097] R2 is hydrogen,
[0098] R3 is cyano,
[0099] R4 is hydrogen,
[0100] X1 is NH,
[0101] and in which the radicals X2, X3, R5, R6 and R7 have in each
case the meanings listed in one of the rows of Table 1 below.
TABLE-US-00001 TABLE 1 Example No. X2 X3 R5 R6 R7 1 N CH methoxy
methoxy methyl 2 N CH methoxy H methyl 3 N CH ethoxy H methyl 4 N
CH H H methyl 5 N CH H methoxy methyl 6 N CH ethoxy methoxy methyl
7 N CH methoxy methoxy ethyl 8 N CH methoxy H ethyl 9 N CH ethoxy H
ethyl 10 N CH H H ethyl 11 N CH H methoxy ethyl 12 N CH ethoxy
methoxy ethyl 13 N CH methoxy methoxy n-propyl 14 N CH methoxy H
n-propyl 15 N CH ethoxy H n-propyl 16 N CH H H n-propyl 17 N CH H
methoxy n-propyl 18 N CH ethoxy methoxy n-propyl 19 N CH methoxy
methoxy isopropyl 20 N CH methoxy H isopropyl 21 N CH ethoxy H
isopropyl 22 N CH H H isopropyl 23 N CH H methoxy isopropyl 24 N CH
ethoxy methoxy isopropyl 25 N CH methoxy methoxy H 26 N CH methoxy
H H 27 N CH ethoxy H H 28 N CH H H H 29 N CH H methoxy H 30 N CH
ethoxy methoxy H 31 CH N methoxy methoxy methyl 32 CH N methoxy H
methyl 33 CH N ethoxy H methyl 34 CH N H H methyl 35 CH N H methoxy
methyl 36 CH N ethoxy methoxy methyl 37 CH N methoxy methoxy ethyl
38 CH N methoxy H ethyl 39 CH N ethoxy H ethyl 40 CH N H H ethyl 41
CH N H methoxy ethyl 42 CH N ethoxy methoxy ethyl 43 CH N methoxy
methoxy n-propyl 44 CH N methoxy H n-propyl 45 CH N ethoxy H
n-propyl 46 CH N H H n-propyl 47 CH N H methoxy n-propyl 48 CH N
ethoxy methoxy n-propyl 49 CH N methoxy methoxy isopropyl 50 CH N
methoxy H isopropyl 51 CH N ethoxy H isopropyl 52 CH N H H
isopropyl 53 CH N H methoxy isopropyl 54 CH N ethoxy methoxy
isopropyl 55 CH N methoxy methoxy H 56 CH N methoxy H H 57 CH N
ethoxy H H 58 CH N H H H 59 CH N H methoxy H 60 CH N ethoxy methoxy
H 61 CH CH methoxy methoxy methyl 62 CH CH methoxy H methyl 63 CH
CH ethoxy H methyl 64 CH CH H H methyl 65 CH CH H methoxy methyl 66
CH CH ethoxy methoxy methyl 67 CH CH methoxy methoxy ethyl 68 CH CH
methoxy H ethyl 69 CH CH ethoxy H ethyl 70 CH CH H H ethyl 71 CH CH
H methoxy ethyl 72 CH CH ethoxy methoxy ethyl 73 CH CH methoxy
methoxy n-propyl 74 CH CH methoxy H n-propyl 75 CH CH ethoxy H
n-propyl 76 CH CH H H n-propyl 77 CH CH H methoxy n-propyl 78 CH CH
ethoxy methoxy n-propyl 79 CH CH methoxy methoxy isopropyl 80 CH CH
methoxy H isopropyl 81 CH CH ethoxy H isopropyl 82 CH CH H H
isopropyl 83 CH CH H methoxy isopropyl 84 CH CH ethoxy methoxy
isopropyl 85 CH CH methoxy methoxy H 86 CH CH methoxy H H 87 CH CH
ethoxy H H 88 CH CH H H H 89 CH CH H methoxy H 90 CH CH ethoxy
methoxy H
[0102] In particular, the present invention relates to the
following compound of the formula Ia (which corresponds to compound
Example 1 of table 1)
##STR00003##
[0103] and also the pharmaceutically acceptable salts, tautomeric
forms, and prodrugs of Ia.
[0104] In particular, the present invention also relates to the
compound Example 7 of table 1 and also to the pharmaceutically
acceptable salts, tautomeric forms, and prodrugs thereof.
[0105] In particular, the present invention also relates to the
compound Example 31 of table 1 and also to the pharmaceutically
acceptable salts, tautomeric forms, and prodrugs thereof.
[0106] In particular, the present invention also relates to the
compound Example 37 of table 1 and also to the pharmaceutically
acceptable salts, tautomeric forms, and prodrugs thereof.
[0107] The compounds (I) or (Ia) of the invention have a centre of
chirality in position 3 of the 2-oxindole ring. The compounds
according to the invention of the general formula (I) or (Ia) may
therefore be present as a 1:1 mixture of enantiomers (racemate), or
as a non-racemic mixture of enantiomers in which one of the two
enantiomers, i.e. either the (laevorotatory) enantiomer which turns
the plane of polarization of linear polarized light to the left
((-)-enantiomer below), or the (dextrorotatory) enantiomer which
turns the plane of polarization of linear polarized light to the
right ((+)-enantiomer below), is enriched, or as essentially
enantiomerically pure compounds (enantiomeric excess ee>90%),
i.e. as essentially enantiomerically pure (-)-enantiomer or
(+)-enantiomer. Preferably, the compounds are present as
essentially enantiomerically pure compounds. Particular preference
is given to compounds which are essentially enantiomerically pure
(ee>90%).
[0108] The invention therefore provides the pure enantiomers as
well as their mixtures, for example, mixtures in which one
enantiomer is present in enriched form, but also the racemates. The
invention also provides the pharmaceutically acceptable salts, the
tautomers and the prodrugs of the pure enantiomers of (I) or (Ia),
and the enantiomer mixtures in the form of the pharmaceutically
acceptable salts, the tautomers and the prodrugs of (I) or
(Ia).
[0109] Preferred embodiments of the invention are compounds of the
general formula (I) or (Ia), as defined above, which are
characterized in that they are present in optically active form and
that they are in each case the enantiomer, which rotates the plane
of polarization of polarized light to the left, (i.e. the
laevorotatory enantiomer) of the compound of the general formula
(I) in question in the form of the free base, or a pharmaceutically
acceptable salt, a tautomeric form or a prodrug thereof. Below, the
laevorotatory enantiomers of the compounds (I) or (Ia) are also
referred to as (-)-enantiomers.
[0110] Preferred embodiments of the invention are those compounds
of the general formula (I) or (Ia), as defined above, which are
characterized in that they are present in optically active form,
where the absolute configuration of the chiral C-3 ring carbon atom
of these compounds corresponds to the absolute configuration at C-3
of the (-)-enantiomer of the compound of the formula (Ia) in the
form of the free base. This configuration is also referred to below
as the "preferred configuration". X-Ray structure analyses have
shown that the (-)-enantiomer of the compounds of the formula (Ia)
has S configuration with respect to the centre of asymmetry at the
carbon atom of position 3 of the oxindole ring.
[0111] According to the invention, preference is given to compounds
of the general formula (I) or (Ia), tautomers thereof,
pharmaceutically acceptable salts thereof and prodrugs thereof, as
defined above, in which the corresponding (-)-enantiomer is present
in an optical purity (enantiomeric excess, ee) of greater than
50%.
[0112] According to the invention, preference is given to compounds
of the general formula (I) or (Ia), tautomers thereof,
pharmaceutically acceptable salts thereof and prodrugs thereof, as
defined above, in which the enantiomer having the preferred
absolute configuration at the C-3 ring carbon atom is present in an
optical purity (enantiomeric excess, ee) of greater than 50%.
[0113] According to the invention, preference is given to compounds
of the general formula (I) or (Ia), tautomers thereof,
pharmaceutically acceptable salts thereof and prodrugs thereof, as
defined above, in which the corresponding (-)-enantiomer is present
in an optical purity (enantiomeric excess, ee) of greater than
90%.
[0114] According to the invention, preference is given to compounds
of the general formula (I) or (Ia), tautomers thereof,
pharmaceutically acceptable salts thereof and prodrugs thereof, as
defined above, in which the enantiomer having the preferred
absolute configuration at the C-3 ring carbon atom is present in an
optical purity (enantiomeric excess, ee) of greater than 90%.
[0115] Likewise preferred embodiments of the invention are
compounds of the general formula (I) or (Ia) as defined above,
which are characterized in that they are present in optically
inactive form, that is to say in the form of the racemate, or in
the form of a pharmaceutically acceptable salt, a tautomeric form
or a prodrug of the racemate.
[0116] A further subject-matter of the present invention relates to
medicaments comprising at least one compound of the general formula
(I) or (Ia) and/or a pharmaceutically acceptable salt or a prodrug
thereof as defined above.
[0117] A further subject-matter of the present invention relates to
compounds of the general formula (I) or (Ia) and/or a
pharmaceutically acceptable salt or a prodrug thereof as defined
above for use as a medicament.
[0118] A further subject-matter of the present invention relates to
the compounds of the formula (I) or (Ia) and/or a pharmaceutically
acceptable salt or a prodrug thereof as defined above for use in
therapy or prophylaxis of a disease, in particular a
vasopressin-dependent disease or a disease mentioned herein.
[0119] A further subject-matter of the present invention relates to
the use of at least one compound of the general formula (I) or (Ia)
and/or a pharmaceutically acceptable salt or a prodrug thereof as
defined above for the treatment and/or prophylaxis of at least one
vasopressin-dependent disease and/or for the manufacture of a
medicament for the treatment and/or a prophylaxis of at least one
vasopressin-dependent disease. Vasopressin-dependent diseases are
those in which the progression of the disease depends at least in
part on vasopressin, i.e. diseases where the vasopressin level,
which may contribute directly or indirectly to the disease picture,
is elevated.
[0120] The present invention also relates to the use of the
compounds (I) or (Ia) according to the invention and/or a
pharmaceutically acceptable salt or a prodrug thereof for the
treatment and/or prophylaxis of diseases in which the progression
of the disease depends at least in part on vasopressin, i.e.
diseases where the vasopressin level, which may contribute directly
or indirectly to the disease picture, is elevated. The present
invention also relates to the use of the compounds (I) or (Ia)
according to the invention and/or a pharmaceutically acceptable
salt or a prodrug thereof for preparing a medicament for the
treatment and/or prophylaxis of such a disease.
[0121] The present invention relates in particular to the use of at
least one compound of the general formula (I) or (Ia) and/or a
pharmaceutically acceptable salt or a prodrug thereof as defined
above for the treatment and/or prophylaxis of at least one disorder
selected from the group consisting of diabetes, in particular
diabetes insipidus, insulin resistance, nocturnal enuresis,
incontinence, diseases in which blood coagulation disorders occur,
and/or for delaying micturition and the use thereof for the
manufacture of a medicament for the treatment and/or prophylaxis of
at least one of said diseases.
[0122] The present invention relates in particular to the use of at
least one compound of the general formula (I) or (Ia) and/or a
pharmaceutically acceptable salt or a prodrug thereof as defined
above for the treatment and/or prophylaxis of at least one disorder
selected from the group consisting of hypertension, pulmonary
hypertension, heart failure, myocardial infarction, coronary spasm,
unstable angina, PTCA (percutaneous transluminal coronary
angioplasty), ischemias of the heart, disorders of the renal
system, edemas, renal vasospasm, necrosis of the renal cortex,
hyponatremia, hypokalemia, Schwartz-Bartter syndrome, disorders of
the gastrointestinal tract, gastritic vasospasm, hepatocirrhosis,
gastric and intestinal ulcer, emesis, emesis occurring during
chemotherapy, and travel sickness, and the use thereof for the
manufacture of a medicament for the treatment and/or prophylaxis of
at least one of said diseases.
[0123] The compounds (I) or (Ia) of the invention, their salts,
their tautomers and their prodrugs can also be used for the
treatment of various vasopressin-dependent complaints which exhibit
central nervous causes or alterations in the HPA axis (hypothalamic
pituitary adrenal axis), for example for affective disorders such
as depressive disorders and bipolar disorders. These include for
example dythymic disorders, phobias, post-traumatic stress
disorders, general anxiety disorders, panic disorders, seasonal
depressions and sleep disorders.
[0124] The compounds (I) or (Ia) of the invention, their salts,
their tautomers and their prodrugs can likewise be employed for
treatment in cases of anxiety disorders and stress-dependent
anxiety disorders such as, for example, generalized anxiety
disorders, phobias, post-traumatic anxiety disorders, panic anxiety
disorders, obsessive-compulsive anxiety disorders, acute
stress-dependent anxiety disorders and social phobia. The compounds
of the invention can further be employed also for the treatment of
memory impairments, Alzheimer's disease, psychoses, psychotic
disorders, sleep disorders and/or Cushing's syndrome, and all
stress-dependent diseases.
[0125] A further subject-matter of the invention relates to the use
of at least one compound of the general formula (I) or (Ia) and/or
a pharmaceutically acceptable salt or a prodrug thereof as defined
above for the treatment of affective disorders and/or for the
manufacture of a medicament for the treatment of affective
disorders.
[0126] A further subject-matter of the invention relates to the use
of at least one compound of the general formula (I) or (Ia) and/or
a pharmaceutically acceptable salt or a prodrug thereof as defined
above for the treatment of anxiety disorders and/or
stress-dependent anxiety disorders and/or for the manufacture of a
medicament for the treatment of anxiety disorders and/or
stress-dependent anxiety disorders.
[0127] A further subject-matter of the invention relates to the use
of at least one compound of the general formula (I) or (Ia) and/or
a pharmaceutically acceptable salt or a prodrug thereof as defined
above for the treatment of memory impairments and/or Alzheimer's
disease and/or for the manufacture of a medicament for the
treatment of memory impairments and/or Alzheimer's disease.
[0128] A further subject-matter of the invention relates to the use
of at least one compound of the general formula (I) or (Ia) and/or
a pharmaceutically acceptable salt or a prodrug thereof as defined
above for the treatment of psychoses and/or psychotic disorders
and/or for the manufacture of a medicament for the treatment of
psychoses and/or psychotic disorders.
[0129] A further subject-matter of the invention relates to the use
of at least one compound of the general formula (I) or (Ia) and/or
a pharmaceutically acceptable salt or a prodrug thereof as defined
above for the treatment of Cushing's syndrome or other
stress-dependent diseases and/or for the manufacture of a
medicament for the treatment of Cushing's syndrome or other
stress-dependent diseases.
[0130] A further subject-matter of the invention relates to the use
of at least one compound of the general formula (I) or (Ia) and/or
a pharmaceutically acceptable salt or a prodrug thereof as defined
above for the treatment of sleep disorders and/or for the
manufacture of a medicament for the treatment of sleep
disorders.
[0131] A further subject-matter of the invention relates to the use
of at least one compound of the general formula (I) or (Ia) and/or
a pharmaceutically acceptable salt or a prodrug thereof as defined
above for the treatment of depressive disorders and/or for the
manufacture of a medicament for the treatment of depressive
disorders.
[0132] A further subject-matter of the invention relates to the use
of at least one compound of the general formula (I) or (Ia) and/or
a pharmaceutically acceptable salt or a prodrug thereof as defined
above for the treatment of childhood onset mood disorders and/or
for the manufacture of a medicament for the treatment of childhood
onset mood disorders. The term "childhood onset mood disorders" is
understood to mean mood disorders and depressions which begin as
early as childhood.
[0133] A further subject-matter of the invention relates to the use
of at least one compound of the general formula (I) or (Ia) and/or
a pharmaceutically acceptable salt or a prodrug thereof as defined
above for the treatment of vasomotor symptoms and/or
thermoregulatory dysfunctions, such as, for example, the "hot
flush" symptom.
[0134] A further subject-matter of the invention relates to the use
of at least one compound of the general formula (I) or (Ia) and/or
a pharmaceutically acceptable salt or a prodrug thereof as defined
above for the treatment and/or prophylaxis of drug dependencies,
medicament dependencies and/or dependencies mediated by other
factors, for the treatment and/or prophylaxis of stress caused by
the withdrawal of one or more factors mediating the dependency
and/or for the treatment and/or prophylaxis of stress-induced
relapses into the drug dependencies, medicament dependencies and/or
dependencies mediated by other factors.
[0135] A further subject-matter of the invention relates to the use
of at least one compound of the general formula (I) or (Ia) and/or
a pharmaceutically acceptable salt or a prodrug thereof as defined
above for the treatment and/or prophylaxis of schizophrenia and/or
psychosis.
[0136] A further subject-matter of the invention relates to a
method for the treatment and/or prophylaxis of at least one
disorder selected from the group consisting of diabetes, in
particular diabetes insipidus, insulin resistance, nocturnal
enuresis, incontinence, diseases in which blood coagulation
disorders occur, and for delaying micturition in a patient,
characterized in that an effective amount of at least one compound
of the general formula (I) or (Ia) and/or a pharmaceutically
acceptable salt or a prodrug thereof is administered to the
patient.
[0137] A further subject-matter of the invention relates to a
method for the treatment and/or prophylaxis of at least one
disorder selected from the group consisting of hypertension,
pulmonary hypertension, heart failure, myocardial infarction,
coronary spasm, unstable angina, PTCA (percutaneous transluminal
coronary angioplasty), ischemias of the heart, disorders of the
renal system, edemas, renal vasospasm, necrosis of the renal
cortex, hyponatremia, hypokalemia, Schwartz-Bartter syndrome,
disorders of the gastrointestinal tract, gastritic vasospasm,
hepatocirrhosis, gastric and intestinal ulcer, emesis, emesis
occurring during chemotherapy, and travel sickness in a patient,
characterized in that an effective amount of at least one compound
of the general formula (I) or (Ia) and/or a pharmaceutically
acceptable salt or a prodrug thereof is administered to the
patient.
[0138] A further subject-matter of the invention relates to a
method for the treatment and/or prophylaxis of affective disorders
in a patient, characterized in that an effective amount of at least
one compound of the general formula (I) or (Ia) and/or a
pharmaceutically acceptable salt or a prodrug thereof is
administered to the patient.
[0139] A further subject-matter of the invention relates to a
method for the treatment of anxiety disorders and/or
stress-dependent anxiety disorders in a patient, characterized in
that an effective amount of at least one compound of the general
formula (I) or (Ia) and/or a pharmaceutically acceptable salt or a
prodrug thereof is administered to the patient.
[0140] A further subject-matter of the invention relates to a
method for the treatment of memory impairments and/or Alzheimer's
disease in a patient, characterized in that an effective amount of
at least one compound of the general formula (I) or (Ia) and/or a
pharmaceutically acceptable salt or a prodrug thereof is
administered to the patient.
[0141] A further subject-matter of the invention relates to a
method for the treatment of psychoses and/or psychotic disorders in
a patient, characterized in that an effective amount of at least
one compound of the general formula (I) or (Ia) and/or a
pharmaceutically acceptable salt or a prodrug thereof is
administered to the patient.
[0142] A further subject-matter of the invention relates to a
method for the treatment of Cushing's syndrome in a patient,
characterized in that an effective amount of at least one compound
of the general formula (I) or (Ia) and/or a pharmaceutically
acceptable salt or a prodrug thereof is administered to the
patient.
[0143] A further subject-matter of the invention relates to a
method for the treatment of sleep disorders in a patient,
characterized in that an effective amount of at least one compound
of the general formula (I) or (Ia) and/or a pharmaceutically
acceptable salt or a prodrug thereof is administered to the
patient.
[0144] A further subject-matter of the invention relates to a
method for the treatment of depressive disorders in a patient,
characterized in that an effective amount of at least one compound
of the general formula (I) or (Ia) and/or a pharmaceutically
acceptable salt or a prodrug thereof is administered to the
patient.
[0145] A further subject-matter of the invention relates to a
method for the treatment and/or prophylaxis of vasomotor symptoms
and/or thermoregulatory dysfunctions, such as, for example, the
"hot flush" symptom, in a patient, characterized in that an
effective amount of at least one compound of the general formula
(I) or (Ia) and/or a pharmaceutically acceptable salt or a prodrug
thereof is administered to the patient.
[0146] A further subject-matter of the invention relates to a
method for the treatment and/or prophylaxis of drug dependencies,
medicament dependencies and/or dependencies mediated by other
factors, for the treatment and/or prophylaxis of stress caused by
the withdrawal of one or more factors mediating the dependency
and/or for the treatment and/or prophylaxis of stress-induced
relapses in the drug dependencies, medicament dependencies and/or
dependencies mediated by other factors, in a patient, characterized
in that an effective amount of at least one compound of the general
formula (I) or (Ia) and/or pharmaceutically acceptable salt or a
prodrug thereof is administered to the patient.
[0147] A further subject-matter of the invention relates to a
method for the treatment and/or prophylaxis of schizophrenia and/or
psychosis in a patient, characterized in that an effective amount
of at least one compound of the general formula (I) or (Ia) and/or
a pharmaceutically acceptable salt or a prodrug thereof is
administered to the patient.
[0148] A further subject-matter of the invention relates to a
method as defined above, which is characterized in that the patient
is a mammal, preferably a human or a nonhuman mammal or a nonhuman
transgenic mammal.
[0149] The compounds of the general formula (I) or (Ia), their
pharmaceutically acceptable salts and prodrugs as defined above can
be prepared by a skilled worker with knowledge of the technical
teaching of the invention in implementation and/or in analogous
implementation of process steps known per se.
[0150] A further preferred embodiment relates to compounds of the
general formula (I) or (Ia), their tautomers, their prodrugs
thereof and their pharmaceutically acceptable salts as described
above, which are characterized in that they are selective for the
vasopressin receptor subtype V1b over at least one of the closely
related vasopressin/oxytocin receptor subtypes (for example
vasopressin V1a, vasopressin V2 and/or oxytocin).
[0151] A further preferred embodiment relates to compounds of the
general formula (I) or (Ia), their tautomers, their prodrugs
thereof and their pharmaceutically acceptable salts as described
above, which are characterized in that they have improved metabolic
stability.
[0152] The metabolic stability of a compound can be determined, for
example, by incubating a solution of this compound with liver
microsomes from particular species (for example rat, dog or human)
and determining the half-life of the compound under these
conditions (R S Obach, Curr Opin Drug Discov Devel. 2001, 4,
36-44). It is possible to conclude from an observed larger
half-life that the metabolic stability of the compound is improved.
The stability in the presence of human liver microsomes is of
particular interest since it makes it possible to predict the
metabolic degradation of the compound in the human liver. Compounds
with increased metabolic stability (determined in the liver
microsome test) are therefore probably also degraded more slowly in
the liver. The slower metabolic degradation in the liver can lead
to higher and/or longer-lasting concentrations (effective levels)
of the compound in the body, so that the elimination half-life of
the compounds according to the invention is increased. Increased
and/or longer-lasting effective levels may lead to a better
efficacy of the compound in the treatment or prophylaxis of various
vasopressin-dependent diseases. An improved metabolic stability may
additionally lead to an increased bioavailability after oral
administration, because the compound is subjected, after being
absorbed in the intestine, to less metabolic degradation in the
liver (so-called first pass effect). An increased oral
bioavailability may, because the concentration (effective level) of
the compound is increased, lead to a better efficacy of the
compound after oral administration.
[0153] A further preferred embodiment relates to compounds of the
general formula (I) as described above, characterized in that, in
patients or relevant animal models allowing prognostic statements
on therapeutic application, they have improved pharmacological
activity compared to the oxindole compounds known from the prior
art.
[0154] Each of the stated preferred definitions of a variable may
be combined with any definitions of the remaining variables.
[0155] The invention relates in particular to compounds of the
general formula (I) which are selected from the group consisting of
the examples, listed below, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,
30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46,
47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63,
64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80,
81, 82, 83, 84, 85, 86, 87, 88, 89 and 90, and also to their
tautomeric forms, their prodrugs and in particular their
physiologically acceptable salts, and their non-salt forms such as
hydrates and/or solvates. Particular preference is given to
providing the abovementioned compounds in the form of the free base
or in the form of acid addition salts.
[0156] The invention in particular also relates to the
(-)-enantiomers of the Examples 1 to 90 in accordance with the
general formula (I) selected from the compounds of the examples,
listed below, 1B, 2B, 3B, 4B, 5B, 6B, 7B, 8B, 9B, 10B, 11B, 12B,
13B, 14B, 15B, 16B, 17B, 18B, 19B, 20B, 21B, 22B, 23B, 24B, 25B,
26B, 27B, 28B, 29B, 30B, 31B, 32B, 33B, 34B, 35B, 36B, 37B, 38B,
39B, 40B, 41 B, 42B, 43B, 44B, 45B, 46B, 47B, 48B, 49B, 50B, 51B,
52B, 53B, 54B, 55B, 56B, 57B, 58B, 59B, 60B, 61B, 62B, 63B, 64B,
65B, 66B, 67B, 68B, 69B, 70B, 71B, 72B, 73B, 74B, 75B, 76B, 77B,
78B, 79B, 80B, 81B, 82B, 83B, 84B, 85B, 86B, 87B, 88B, 89B and 90B,
and also to tautomeric forms, prodrugs and in particular
physiologically acceptable salts, and non-salt forms such as
hydrates and/or solvates of compounds of the formula (I).
Particular preference is given to providing the abovementioned
compounds in the form of the free base or in the form of acid
addition salts.
[0157] The term "prodrugs" is to be understood as meaning those
compounds which are metabolized in vivo to the compounds according
to the invention. Typical examples of prodrugs are described in C.
G. Wermeth (Ed.): The Practice of Medicinal Chemistry, Academic
Press, San Diego, 1996, pages 671-715. They include, for example,
phosphates, carbamates or amino acids, esters and others. In the
present invention suitable prodrugs of the compounds of the formual
are compounds of the formula I, where the nitrogen atom that
carries R7 is part of an amide/peptide group, i.e. the nitrogen
carries a acyl group such as C1-C4-alkylcarbonyl e.g. acetyl,
propionyl, n-butyryl (n-propylcarbonyl), isobutyryl,
n-butylcarbonyl oder tert-butylcarbonyl (pivaloyl), benzoyl, CO
bound radical derived from an amino acid such as a CO bound radical
derived from glycine, alanine, serine, phenylalanine etc. Suitable
prodrugs olso include alkylcarbonyloxyalkylcarbamate, wherein the
radical R7 in formula I is a moiety of the formula
--C(.dbd.O)--O--CHR.sup.a--O--C(.dbd.O)--R.sup.b wherein R.sup.a
and R.sup.b are independently of each other are selected from
C.sub.1-C.sub.4-alkyl. Such carbamates have been generally
described by J. Alexander, R. Cargill, S. R. Michelson, H. Schwam,
J. Medicinal Chem. 1988, 31(2), 318-322. These groups are cleaved
under metabolic conditions to yield a compound of the formula I,
wherein R7 is hydrogen.
[0158] The invention furthermore relates to the pharmaceutically
acceptable salts of compounds of the formula I, which are also
referred to as physiologically acceptable salts. The salts are
generally obtainable by reacting the free base of the compounds (I)
according to the invention with a suitable acid. Suitable acids are
listed, for example, in "Fortschritte der Arzneimittelforschung"
[Advances in Drug Research], 1966, Birkhauser Verlag, Vol. 10, pp.
224-285. They include, for example, hydrochloric acid, citric acid,
tartaric acid, lactic acid, phosphoric acid, methanesulphonic acid,
acetic acid, formic acid, maleic acid and fumaric acid.
[0159] The compounds of the invention are effective after
administration by various routes. The administration can, for
example, be carried out intravenously, intramuscularly,
subcutaneously, topically, intratracheally, intranasally,
transdermally, vaginally, rectally, sublingually, buccally or
orally and is frequently carried out intravenously, intramuscularly
or in particular orally.
[0160] The present invention also relates to pharmaceutical
compositions which comprise a compound (I) of the invention, and/or
a tautomer, and/or a pharmaceutically acceptable salt and/or a
prodrug thereof and suitable pharmaceutical carriers (drug
carriers). The amount of compound I in the pharmaceutical
composition may depend on the formulation type of the composition
and may be e.g. in the range from 0.0001 mg/g to 1 g/g in
particular from 0.001 mg/g to 0.5 g/g of the composition.
[0161] These drug carriers are chosen according to the
pharmaceutical form and the desired mode of administration.
[0162] The compounds of the invention of the general formula (I)
or, where appropriate, suitable salts of these compounds can be
used to manufacture pharmaceutical compositions for oral,
sublingual, buccal, subcutaneous, intramuscular, intravenous,
topical, intratracheal, intranasal, transdermal, vaginal or rectal
administration and be administered to animals or humans in unit
dose forms mixed with conventional pharmaceutical carriers for the
prophylaxis or treatment of the above disorders or diseases.
[0163] Suitable uniform administration forms (unit dose forms)
comprise forms for oral administration, such as tablets, gelatin
capsules, powders, granules, solutions or suspensions for oral
intake, forms for sublingual, buccal, intratracheal or intranasal
administration, aerosols, implants, forms of subcutaneous,
intramuscular or intravenous administration and forms of rectal
administration.
[0164] The compounds of the invention can be used in creams,
ointments or lotions for topical administration.
[0165] In order to achieve the desired prophylactic or therapeutic
effect, the dose of the active compound can vary between 0.01 and
50 mg per kg of body weight and per day.
[0166] Each unit dose may comprise from 0.05 to 5000 mg, preferably
1 to 1000 mg, of the active compound in combination with a
pharmaceutical carrier. This unit dose can be administered 1 to 5
times a day so that a daily dose of from 0.5 to 25 000 mg,
preferably 1 to 5000 mg, is administered.
[0167] If a solid composition in the form of tablets is prepared,
the active compound is mixed with a pharmaceutical carrier such as
gelatin, starch, lactose, magnesium stearate, talc, silicon dioxide
or the like.
[0168] The tablets can be coated with sucrose, a cellulose
derivative or another suitable substance or be treated otherwise in
order to display a prolonged or delayed activity and in order to
release a predetermined amount of the active compound
continuously.
[0169] A preparation in the form of gelatin capsules is obtained by
mixing the active compound with an extender and taking up the
resulting mixture in soft or hard gelatin capsules.
[0170] A preparation in the form of a syrup or elixir or for
administration in the form of drops may comprise active compounds
together with a sweetener which is preferably calorie-free,
methylparaben or propylparaben as antiseptics, a flavouring and a
suitable colouring.
[0171] The water-dispersible powders or granules may comprise the
active compounds mixed with dispersants, wetting agents or
suspending agents, such as polyvinylpyrrolidones, and sweeteners or
taste improvers.
[0172] Rectal or vaginal administration is achieved by the use of
suppositories which are prepared with binders which melt at the
rectal temperature, for example cocoa butter or polyethylene
glycols. Parenteral administration is effected by using aqueous
suspensions, isotonic salt solutions or sterile and injectable
solutions which comprise pharmacologically suitable dispersants
and/or wetting agents, for example propylene glycol or polyethylene
glycol.
[0173] The active compound can also be formulated as microcapsules
or centrosomes, if suitable with one or more carriers or
additives.
[0174] In addition to the compounds of the general formula (I), or
their pharmaceutically acceptable salts or prodrugs, the
compositions of the invention may comprise further active compounds
which may be beneficial for the treatment of the impairments or
disorders indicated above.
[0175] The present invention therefore further relates to
pharmaceutical compositions which comprise a plurality of active
compounds, where at least one of these is a compound (I) according
to the invention, a tautomer, a salt or a prodrug thereof.
PREPARATION OF THE COMPOUNDS OF THE INVENTION
[0176] Examples of synthetic routes for preparing the oxindole
derivatives of the invention are described below.
[0177] The preparation of the oxindoles according to the invention
can be carried out by different routes as illustrated in synthesis
schemes 1 and 2. In these synthesis schemes, the variables have the
same meanings as in the general formula (I).
[0178] The 3-hydroxy-1,3-dihydroindol-2-ones IV can be obtained by
adding metallated heterocycles III to the 3-keto group of the
isatins II. The metallated heterocycles, such as, for example, the
corresponding Grignard (Mg) or organyllithium compound, can be
obtained in a customary manner from halogen or hydrocarbon
compounds. Exemplary procedures can be found in Houben-Weyl,
Methoden der Organischen Chemie [Methods of organic chemistry],
Vol. 13, 1-2, Chap. Mg and Li compounds. The isatins II are either
commercially available or were prepared in analogy to methods
described in the literature (Advances in Heterocyclic Chemistry, A.
R. Katritzky and A. J. Boulton, Academic Press, New York, 1975, 18,
2-58; J. Brazil. Chem. Soc. 12, 273-324, 2001).
[0179] Using KCN or Zn(CN).sub.2 with Pd(0) catalysis in solvents
such as dimethylformamide or tetrahydrofuran, if appropriate also
with addition of bases such as K.sub.2CO.sub.3 or other carbonates
and amines, it is possible to convert, at elevated temperature, the
3-hydroxyoxindoles IV which, in the 6-membered aromatic ring
contain, for example as radical R.sup.3 or R.sup.4, an iodine
substituent, into the analogous cyano-containing
3-hydroxy-oxindoles IV. Suitable for use as Pd(0) salts are, for
example, transition metal complexes prepared in situ from
PdCl.sub.2 or PdOAc.sub.2 by addition of phosphines, such as
tris(orthotolyl)phosphine. It is also possible to use commercial
palladium complexes, such as, for example, the catalyst
tetrakis(triphenylphosphine)palladium(0) and/or added phosphine
ligands.
[0180] The 3-hydroxyoxindoles IV can be converted into the
compounds V which carry a leaving group LG' in position 3, where
the leaving group LG' may be a customary leaving group, such as,
for example, halide, mesylate or tosylate. The intermediate V
where, for example, LG'=chlorine, can be prepared by treating the
alcohol IV with thionyl chloride in the presence of a base, such
as, for example, pyridine. Alternatively, it is possible to obtain
alcohols IV by conversion into the mesylate using methanesulphonyl
chloride in the presence of a base, such as, for example,
triethylamine. The compounds V are subsequently reacted with
amines, such as, for example, ammonia, which gives the analogous
amines VI after the substitution reactions. Compounds such as VI
can then, after deprotonation with a strong base, such as, for
example, potassium tert-butoxide or sodium hydride, in DMF, be
converted into the product VIII by treatment with sulphonyl
chlorides VII. The sulphonyl chlorides VII used are either
commercially available or can be prepared in a manner analogous to
known processes (see, for example, J. Med. Chem. 40, 1149
(1997)).
[0181] The compounds VIII are converted into compounds IX by
reaction with reagents for derivatizing amino groups, such as, for
example chloroformates, isocyanates or carbamoyl chlorides,
generally using customary methods (see J. March, Advanced Organic
Chemistry, 1992, 4th edition., Wiley, N.Y., pages 417-421; 499;
903). For example, LG as leaving group may be OPhenyl in the
compound IX, which is obtained by reacting VIII with phenyl
chloroformate in the presence of a base, such as, for example,
pyridine.
[0182] The subsequent reaction with amines X, if appropriate at
elevated temperature and with addition of auxiliary bases, such as,
for example, triethylamine or diisopropylethylamine, gives the
compounds according to the invention of the general formula (I).
The amines X are either commercially available or can be prepared
by methods known from the literature.
[0183] A further alternative of preparing the amine X is the
reaction of amines with aldehydes or ketones in the presence of
reducing agents, such as, for example, sodium cyanoborohydride or
sodium acetoxyborohydride, in the sense of a reductive amination
(J. March, Advanced Organic Chemistry, 1992, 4th edition., Wiley,
N.Y., pages 411; 898).
##STR00004## ##STR00005##
[0184] As described in synthesis scheme 2, the order of the
synthesis steps for preparing the compounds I according to the
invention may be rearranged, analogously to synthesis scheme 1
above. Thus, initially, the amino group in the compound VI is
derivatized using, for example, phenyl chloroformate, giving the
compounds XIa and/or XIb. With excess amine X or else with the aid
of an auxiliary base, the urea derivatives XII are generated which
can be converted in the subsequent reaction under otherwise
customary conditions by deprotonation of compounds XII using a
strong base, such as, for example, sodium hydride or potassium
tert-butoxide, and subsequent treatment with sulphonyl chlorides
VII in DMF into the compounds I according to the invention.
##STR00006##
[0185] Below, the invention is illustrated in more detail using
examples, the examples not being intended to be limiting.
[0186] The compounds according to the invention can be prepared via
various synthesis routes.
[0187] The procedures mentioned, as described accordingly in
synthesis schemes 1 and 2, are only described in greater detail by
way of example on the basis of the examples mentioned, without
being exclusively limited to the synthesis routes 1 or 2 or
analogous procedures mentioned.
EXPERIMENTAL PART
EXAMPLE 1
N-[5-Cyano-1-[(2,
4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1-
H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carboxamide
1a)
3-(2-Ethoxypyridin-3-yl)-3-hydroxy-5-iodo-1,3-dihydro-2H-indol-2-one
[0188] With ice-bath cooling, 20.86 g (76.40 mmol) of 5-iodoisatin
were stirred in 400 ml of anhydrous tetrahydrofuran (THF), and 3.22
g (80.50 mmol, 60% w/w) of sodium hydride were added a little at a
time, the temperature being kept between 0-10.degree. C. With
ice-bath cooling, the suspension was stirred for one hour, during
which the pyridine Grignard reagent was prepared. At room
temperature, 20 g (80.30 mmol) of the 2-ethoxy-3-iodopyridine were
dissolved in 400 ml of anhydrous THF, and over a period of 5-10
minutes 95.6 ml (1M solution in THF, 95.60 mmol) of ethylmagnesium
bromide were added to this solution with cooling, at a temperature
between 22 and 15.degree. C. The solution was stirred for 20
minutes, during which time the colour changed from colourless to
slightly yellowish.
[0189] The solution of the pyridine Grignard reagents was then,
over a period of 5-10 minutes, added to the solution, cooled in an
ice-bath, of the 5-iodoisatin sodium salt, the temperature
fluctuating between 5 and 18.degree. C. After the addition of the
Grignard reagent had ended, the ice-bath was removed, and the
reaction mixture was stirred at room temperature for another 2
hours. Excess saturated ammonium chloride solution was added,
followed by ethyl acetate, and the mixture was stirred for another
5 minutes. The aqueous phase was removed and extracted with ethyl
acetate (2.times.). The combined organic phases were washed with
water (2.times.), and the solvent was removed under reduced
pressure. Initially, unreacted 5-iodoisatin precipitated from the
still dilute solution and was removed, and after further
concentration the product, too, crystallized out. The suspension
was stored in a refrigerator at 5.degree. C. for two hours and the
slightly yellowish solid was then filtered off and washed with a
little ethyl acetate. The desired
3-(2-ethoxypyridin-3-yl)-3-hydroxy-5-iodo-1,3-dihydro-2H-indol-2--
one (17.1 g, 43.16 mmol, 57%) was isolated after drying at
40.degree. C.
[0190] ESI-MS [M+H.sup.+]=397.05 calculated for
C.sub.15H.sub.13IN.sub.2O.sub.3=396.19
1b)
5-Cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one
[0191] Under an atmosphere of nitrogen, 7.1 g (17.92 mmol) of
3-(2-ethoxypyridin-3-yl)-3-hydroxy-5-iodo-1,3-dihydro-2H-indol-2-one
were stirred in 100 ml of anhydrous THF at room temperature. 2.1 g
(17.92 mmol) of zinc cyanide were added, followed by 0.51 g (0.45
mmol) of tetrakis(triphenylphosphine)palladium(0). The reaction
mixture was transferred directly into a preheated oil bath at a
temperature of 100.degree. C. The mixture was stirred at
100.degree. C. (oil bath temperature), and after 30 minutes,
another 0.51 g (0.45 mmol) of the catalyst was added. In total, the
mixture was stirred for 2 hours. The reaction mixture was cooled to
room temperature, and an excess of water was added. The mixture was
extracted with ethyl acetate (3.times.), and the combined organic
phases were washed with water (3.times.). The solvent was
evaporated to dryness under reduced pressure, and the residue was
slurried with small volumes of ethyl acetate. A slightly yellowish
solid was removed by filtration, washed with ethyl acetate and
dried in a vacuum drying cabinet. It was possible to isolate 3.7 g
(12.44 mmol, 69.4%) of the desired product
5-cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one.
[0192] ESI-MS [M+H.sup.+]=296.05 calculated for
C.sub.16H.sub.13N.sub.3O.sub.3=295.30
1c)
3-Chloro-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile
[0193] Under an atmosphere of nitrogen, 6.00 g (20.32 mmol) of the
5-cyano-3-hydroxy-3-(2-ethoxypyridin-3-yl)-1,3-dihydroindol-2-one
were suspended in 60 ml of anhydrous dichloromethane (dried over
molecular sieve). 2.30 ml (28.45 mmol) of pyridine were then added.
The reaction mixture was cooled to a temperature of 0.degree. C.,
and 2.06 ml (28.45 mmol) of neat thionyl chloride were then added
dropwise (exothermic reaction). The mixture was stirred at room
temperature for one hour. The formation of a yellow suspension was
observed. The course of the reaction was monitored by thin-layer
chromatography (TLC) (silica gel, dichloromethane/methanol in a
ratio of 95:5). The reaction mixture was carefully poured into
ice-water. After 15 minutes of stirring, the organic phase was
removed. The aqueous phase was extracted with dichloromethane
(2.times.). All organic phases were combined, dried over magnesium
sulphate and filtered, and the solvent was removed under reduced
pressure. The product gave 5.70 g (18.17 mmol, 89%) of
3-chloro-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile as
an amorphous solid which was used without further purification for
the next reaction.
[0194] ESI-MS [M+H.sup.+]=314.1 calculated for
C.sub.16H.sub.12CIN.sub.3O.sub.2=313.75
1d)
3-Amino-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile
[0195] 5.70 g (18.17 mmol) of
3-chloro-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile were
dissolved in 50 ml of dichloromethane. Under an atmosphere of
nitrogen, 14 ml (98.11 mmol) of a 7 N methanolic ammonia solution
were slowly added dropwise to the cooled reaction solution. The
colour of the solution changed to light-yellow, and the solution
was stirred at room temperature overnight, during which time the
product slowly crystallized out. The course of the reaction was
monitored by TLC (silica gel, dichloromethane/methanol in a ratio
of 9:1). The solvent was removed under reduced pressure, and the
residue was once more taken up and dissolved in dichloromethane.
The mixture was then extracted with water. The phases were
separated, and a greasy phase which had formed between the phases
was added to the aqueous phase. The aqueous phase was extracted
with ethyl acetate until the greasy phase had gone into solution.
All organic phases obtained were combined, and the solvent was
removed under reduced pressure. The residue was triturated with
diethyl ether, resulting in the formation of a solid substance
which was filtered off and dried in a vacuum drying cabinet at
moderate temperature (35.degree. C.). This gave 4.54 g (15.43 mmol,
85%) of the
3-amino-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile as a
solid.
[0196] ESI-MS [M+H.sup.+]=295.3 calculated for
C.sub.16H.sub.14N.sub.4O.sub.2=294.32
1e)
3-Amino-1-[2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xoindoline-5-carbonitrile
[0197] 3.54 g (12.03 mmol) of
3-amino-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile were
dissolved in 80 ml of anhydrous dimethylformamide (dried over
molecular sieve). Under an atmosphere of nitrogen and with cooling
using an ice-bath, 1.49 g (13.23 mmol) of potassium tert-butoxide
were added a little at a time. The colour of the reaction mixture
changed, and the brown solution was stirred at 0.degree. C. for
another hour to ensure that the deprotonation proceeded to
completion. At low temperature, 3.16 g (13.23 mmol)
2,4-dimethoxybenzenesulphonyl chloride were added, and the mixture
was stirred at 0.degree. C. for another two hours. The course of
the reaction was monitored by TLC (silica gel,
dichloromethane/methanol in a ratio of 9:1). The reaction mixture
was poured into ice-water and then extracted with ethyl acetate.
The organic phase was washed with saturated sodium chloride
solution and dried over magnesium sulphate, and the solvent was
evaporated. The residue was suspended in diethyl ether and stirred
until the product precipitated as a solid and could be removed by
filtration. After removal of the solvent, the mother liquor was
once more treated with diethyl ether (2.times.) until finally,
after drying, 4.67 g (9.44 mmol, 79%) of the desired
3-amino-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-
indoline-5-carbonitrile were obtained as a solid substance.
[0198] ESI-MS [M+H.sup.+]=495.15 calculated for
C.sub.24H.sub.22N.sub.4O.sub.6S=494.53
1f)
Phenyl[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate
[0199] 4.67 g (9.44 mmol) of
3-amino-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-
indoline-5-carbonitrile were dissolved in 120 ml of pyridine and
cooled to 0.degree. C. using an ice-bath. 1.30 ml (10.39 mmol) of
neat phenyl chloroformate were added, and the reaction mixture was
stirred at 0.degree. C. for 2 hours. The course of the reaction was
monitored by TLC (silica gel, dichloromethane/methanol in a ratio
of 95:5). The solvent and especially pyridine were removed under
reduced pressure, and the residue was diluted with water and
extracted with ethyl acetate (3.times.). The combined organic
phases were washed with saturated sodium chloride solution, dried
over magnesium sulphate and filtered, and the solvent was removed
under reduced pressure. Traces of pyridine were removed by repeated
addition of toluene and evaporation on a rotary evaporator. Diethyl
ether was added to the isolated residue, and a solid crystallized
overnight giving 5.62 g (9.14 mmol, 97%) of the desired product
phenyl[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)-2-oxo-2,3-dihydro-1H-indole-3-yl]carbamate.
[0200] ESI-MS [M+H.sup.+]=615.15 calculated for
C.sub.31H.sub.26N.sub.4O.sub.8S=614.64
1g)
N-[5-Cyano-1-1(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-c-
arboxamide
[0201] 1.00 g (1.63 mmol) of
phenyl[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate, 596 mg (3.25 mmol) of
1-(1-methylpiperidin-4-yl)piperazine and 8 ml of dried THF were
combined and the mixture was stirred at room temperature for 24
hours. The end of the reaction was detected with the aid of
analytical HPLC (RP, eluents acetonitrile/water, 0.01% TFA). The
solvent was removed, and the residue was purified by preparative
HPLC using dichloromethane and 6% methanol as eluents on a
Chromolith column (normal phase, from Merck). After repeated column
chromatography, it was possible to isolate 230 mg (0.33 mmol, 21%)
of the
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-
-1-carboxamide.
[0202] Alternatively, work-up and purification after the reaction
had ended could be carried out as follows: the solvent was removed.
The crude material was dissolved in ethyl acetate and extracted
with 1 N HCl. The impurities were detected in the organic phase,
the product being in the acidic aqueous phase. Accordingly, the
aqueous phase was neutralized with 2 N NaOH solution and extracted
with ethyl acetate. After drying over magnesium sulphate,
filtration and removal of the ethyl acetate under reduced pressure,
the product could be crystallized with diethyl ether. The
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1--
carboxamide was obtained in yields of >50%.
[0203] ESI-MS [M+H.sup.+]=704.2 calculated for
C.sub.35H.sub.41N.sub.7O.sub.7S=703.82
[0204] .sup.1H-NMR ([D6]-DMSO, 400 MHz) .delta. [ppm]=8.12 (d, 1H,
J=4.8 Hz), 7.88 (d, 1H, J=8.8 Hz), 7.87 (d, 1H, J=8.7 Hz), 7.81 (d,
1H, J=8.5 Hz), 7.72 (d, 1H, J=7.6 Hz), 7.67 (s, 1H), 7.64 (s, 1H),
7.02 (dd, 1H, J=5.0 Hz, J=7.5 Hz), 6.69 (d, 1H, J=8.9 Hz), 6.65 (s,
1H), 4.15 (m, 2H), 3.85 (s, 3H), 3.44 (s, 3H), 3.20 (m, 4H), 2.76
(m, 2H, J=11.1 Hz), 2.34 (m, 4H), 2.11 (m, 4H), 1.81 (m, 2H, J=11.3
Hz), 1.64 (m, 2H, J=10.7 Hz), 1.37 (m, 2H), 1.06 (t, 1H, J=7.0
Hz).
EXAMPLE 5
N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2-oxo-2-
,3-dihydro-1H-indol-3-yl}-4-(1-methylpiperidin-4-yl)piperazine-1-carboxami-
de
5a) Phenyl
5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-3-[(phenoxycarbonyl)amin-
o]-indoline-2-carboxylate
[0205] 2.78 g (9.43 mmol) of
3-amino-3-(2-ethoxypyridin-3-yl)-2-oxoindoline-5-carbonitrile
(prepared according to Example 1, process steps 1a) to 1c)) were
suspended in 25 ml of dichloromethane and cooled with an ice-bath
to 0.degree. C. 7.63 ml (94.34 mmol) of pyridine were added, and
2.37 ml (18.87 mmol) of phenyl chloroformate were then added slowly
dropwise such that the temperature did not exceed 5-10.degree. C.
With thawing of the ice-bath, the reaction was stirred at room
temperature overnight, and a lightly coloured solid precipitated
out. The reaction mixture was diluted with dichloromethane, and
after addition of water, the solid went back into solution. The
phases were separated and the aqueous phase was again extracted
with dichloromethane (1.times.). The combined organic phases were
washed initially with water (3.times.) and then with saturated
sodium chloride solution (1.times.). After drying over magnesium
sulphate, filtration and evaporation of the solvent under reduced
pressure, the residue was subjected to incipient dissolution in
diethyl ether, and 10 times the amount of pentane was added. A
white precipitate formed, and this was filtered off with suction,
washed with pentane and dried in a vacuum drying cabinet at
40.degree. C. After fractional crystallization, a total of 4.46 g
(8.35 mmol, 89%) of phenyl
5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-3-[(phenyloxycarbonyl)amino]indoli-
ne-1-carboxylate were isolated.
[0206] ESI-MS [M+H.sup.+]=535.15 calculated for
C.sub.30H.sub.22N.sub.4O.sub.6=534.53
5b)
N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-
-(1-methylpiperidin-4-yl)piperazine-1-carboxamide
[0207] 760 mg (1.42 mmol) of phenyl
5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-3-[phenoxy-carbonyl)amino]indoline-
-1-carboxylate were initially charged in 5 ml of THF, and 1.42 g
(5.69 mmol) of 1-(1-methylpiperidin-4-yl)piperazine were added
undiluted at room temperature. The reaction mixture was stirred
overnight, and the reaction was checked by TLC (silica gel,
dichloromethane/methanol 15:5) to determine the progress of the
reaction. The reaction was diluted with ethyl acetate and washed
with water (1.times.) and saturated sodium chloride solution
(1.times.). The organic phase was dried over magnesium sulphate and
filtered, and the solvent was removed under reduced pressure. The
residue was taken up in a little diethyl ether, and 6 times the
amount of cyclohexane was added. A colourless solid comprising 615
mg (1.22 mmol, 86%) of pure
N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-
-methylpiperidin-4-yl)piperazine-1-carboxamide precipitated
out.
[0208] ESI-MS [M+H.sup.+]=504.25 calculated for
C.sub.27H.sub.33N.sub.7O.sub.3=503.61
5c)
N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2-o-
xo-2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carbo-
xamide
[0209] 80.0 mg (0.16 mmol) of
N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-
-methylpiperidin-4-yl)piperazine-1-carboxamide were dissolved in
dimethylformamide, and 7.63 mg (0.19 mmol, 60% w/w) of sodium
hydride were added at 0.degree. C. For the deprotonation of the
1,3-dihydro-2H-indol-2-on derivative, the mixture was stirred for
10 minutes, and 39.4 mg (0.19 mmol) of 4-methoxybenzenesulphonyl
chloride were then added. The mixture was then allowed to warm to
room temperature and stirred for 30 minutes. The progress of the
reaction was monitored by TLC (silica gel, dichloromethane/methanol
1:1). Saturated sodium bicarbonate solution and ethyl acetate were
added to the reaction mixture, and the phases were then separated.
The aqueous phase was reextracted with ethyl acetate (1.times.).
The combined organic phase was washed with water (1.times.) and
saturated sodium chloride solution (1.times.), dried over magnesium
sulphate and filtered, and the solvent was removed under reduced
pressure. The residue was purified by preparative MPLC (ISCO
Companion, 4 g NP cartridge) using the mobile phases
dichloromethane/methanol (5-20%). What was isolated were 27.3 mg
(0.04 mmol, 23% yield, 90% purity) of
N-[5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2-oxo--
2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carboxam-
ide.
[0210] ESI-MS [M+H.sup.+]=674.2 calculated for
C.sub.34H.sub.39N.sub.7O.sub.6S=673.80
[0211] Alternative purification methods to the crystallization of
the crude mixtures include the conventional column chromatography
on a normal phase (NP-SiO.sub.2 cartridge, Chromabond) using the
mobile phases dichloromethane/methanol and the preparative HPLC
(RP, mobile phase acetonitrile/water, 0.01% TFA or 0.01% acetic
acid).
EXAMPLES 2 TO 4 AND 6 TO 30
[0212] The compounds according to Examples 2 to 4 and 6 to 30 can
be prepared in a manner analogous to the preparation procedures
according to Example 1 and/or Example 5 using the appropriate
starting materials.
EXAMPLE 2
N-{5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2-oxo-2-
,3-dihydro-1H-indol-3-yl}-4-(1-methylpiperidin-4-yl)piperazine-1-carboxami-
de
[0213] ESI-MS [M+H.sup.+]=674.05 calculated for
C.sub.34H.sub.39N.sub.7O.sub.6S=673.80
EXAMPLE 3
N-[5-Cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2,-
3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carboxamid-
e trifluoroacetate
[0214] ESI-MS [M+H.sup.+]=688.3 calculated for
C.sub.35H.sub.41N.sub.7O.sub.6S=687.82
EXAMPLE 4
N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dihydro--
1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carboxamide
[0215] ESI-MS [M+H.sup.+]=644.2 calculated for
C.sub.33H.sub.37N.sub.7O.sub.5S=643.77
EXAMPLE 31
N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carbo-
xamide
[0216] 100 mg (0.16 mmol) of the
phenyl[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate (prepared according to
Example 1, process steps 1a) to 1f)) were initially charged in 8 ml
of anhydrous tetrahydrofuran (dried over molecular sieve), and 44.7
mg (0.24 mmol) of 1-methyl-4-(piperidin-4-yl)piperazine were added.
The reaction mixture was stirred at room temperature overnight. The
course of the reaction was monitored by TLC (silica gel,
dichloromethane/methanol in a ratio of 9:1) and LCMS (RP,
acetonitrile/water as eluents and 0.01% TFA). The solvent was
removed under reduced pressure, and the residue was taken up in
dichloromethane and extracted with 2 N sodium hydroxide solution
(1.times.). The combined organic phases were dried over magnesium
sulphate and filtered, and the solvent was removed under reduced
pressure. The crude mixture was purified twice by column
chromatography (5 g NP-SiO.sub.2 cartridge Chromabond) using
dichloro-methane/methanol in a ratio of 99:1 to 80:20 as eluent.
What was isolated were 53.8 mg (0.08 mmol, 47%) of pure
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carb-
oxamide.
[0217] ESI-MS [M+H.sup.+]=704.25 calculated for
C.sub.35H.sub.41N.sub.7O.sub.7S=703.82
[0218] .sup.1H-NMR ([D6]-DMSO, 400 MHz) .delta. [ppm]=8.13 (dd, 1H,
J=1.4 Hz, J=4.8 Hz), 7.88 (d, 1H, J=8.5 Hz), 7.87 (d, 1H, J=8.8
Hz), 7.81 (dd, 1H, J=1.6 Hz, J=8.6 Hz), 7.71 (dd, 1H, J=1.4 Hz,
J=7.6 Hz), 7.68 (d, 1H, J=1.3 Hz), 7.65 (s, 1H), 7.02 (dd, 1H,
J=4.9 Hz, J=7.6 Hz), 6.68 (d, 1H, J=8.9 Hz), 6.65 (s, 1H), 4.17 (m,
2H), 3.85 (s, 3H), 3.80 (m, 2H), 3.44 (s, 3H), 2.62 (m, 2H),
2.41-2.12 (m, 9H), 2.12 (s, 3H), 1.61 (m, 2H), 1.16 (m, 2H), 1.09
(t, 3H, J=7.0 Hz).
EXAMPLES 32 TO 36
[0219] The compounds according to Examples 32 to 36 can be prepared
in a manner analogous to the preparation procedures according to
Example 1, 5 and/or 31 using the appropriate starting
materials.
EXAMPLE 32
N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2-oxo-2-
,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carboxami-
de
[0220] ESI-MS [M+H.sup.+]=674.8 calculated for
C.sub.34H.sub.39N.sub.7O.sub.6S=673.80
EXAMPLE 33
N-[5-Cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-oxo-2,-
3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carboxamid-
e trifluoroacetate
[0221] ESI-MS [M+H.sup.+]=688.2 calculated for
C.sub.35H.sub.41N.sub.7O.sub.6S=687.82
EXAMPLE 34
N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dihydro--
1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carboxamide
[0222] ESI-MS [M+H.sup.+]=644.7 calculated for
C.sub.33H.sub.37N.sub.7O.sub.5S=643.77
EXAMPLE 35
N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2-oxo-2-
,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carboxami-
de trifluoroacetate
[0223] ESI-MS [M+H.sup.+]=674.2 calculated for
C.sub.34H.sub.39N.sub.7O.sub.6S=673.80
EXAMPLE 37
N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-carbox-
amide
[0224] 100 mg (0.16 mmol) of the
phenyl[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate (prepared according to
Example 1, process steps 1a) to 1f)), dissoved in 8 ml of anhydrous
tetrahydrofuran (dried over molecular sieve) were initially
charged. 74.9 mg (0.24 mmol) of 1-ethyl-4-piperidin-4-ylpiperazine
and 0.07 ml of triethylamine were added together to the reaction
mixture, which was then stirred at room temperature overnight. To
accelerate the reaction and to achieve complete conversion, the
mixture was again heated to 50.degree. C. The course of the
reaction was monitored by TLC (silica gel, dichloromethane/methanol
in a ratio of 9:1) and LCMS (RP, acetonitrile/water as eluents and
0.01% TFA). The solvent was removed under reduced pressure, and the
residue was taken up in dichloromethane and extracted with 2 N
sodium hydroxide solution (1.times.). The combined organic phases
were dried over magnesium sulphate and filtered, and the solvent
was removed under reduced pressure. The crude mixture was purified
initially by column chromatography of silica gel (column
20.times.200 mm) using dichloromethane and 2% methanol as eluents.
The combined, still slightly contaminated product fractions were
purified again by preparative HPLC on a Chromolith column (normal
phase, from Merck) using the eluents dichloromethane and methanol
(gradient 0-10% by volume of methanol over 15 min.). This gave 20
mg (0.03 mmol, 17%) of the desired
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin--
3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-
-1-carboxamide.
[0225] ESI-MS [M+H.sup.+]=718.25 calculated for
C.sub.36H.sub.43N.sub.7O.sub.7S=717.85
[0226] .sup.1H-NMR ([D6]-DMSO, 400 MHz) .delta. [ppm]=8.13 (dd, 1H,
J=1.2 Hz, J=4.6 Hz), 7.88 (d, 1H, J=8.2 Hz), 7.87 (d, 1H, J=8.7
Hz), 7.81 (dd, 1H, J=1.4 Hz, J=8.6 Hz), 7.72 (dd, 1H, J=1.3 Hz,
J=7.6 Hz), 7.68 (d, 1H, J=1.1 Hz), 7.66 (s, 1H), 7.02 (dd, 1H,
J=4.9 Hz, J=7.6 Hz), 6.68 (dd, 1H, J=2.0 Hz, J=8.8 Hz), 6.65 (d,
1H, J=2.2 Hz), 4.17 (m, 2H), 3.85 (s, 3H), 3.81 (m, 2H), 3.44 (s,
3H), 2.62 (m, 2H), 2.43-2.29 (m, 11H), 1.61 (m, 2H), 1.15 (m, 2H),
1.09 (t, 3H, J=7.0 Hz), 0.97 (t, 3H, J=7.1 Hz).
EXAMPLES 38 TO 90
[0227] The compounds according to Examples 38 to 90 can be prepared
in a manner analogous to the preparation procedures according to
Examples 1, 5, 31, 37, 55, 61 and/or 67 using the appropriate
starting materials.
EXAMPLE 40
N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dihydro--
1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxamide
[0228] ESI-MS [M+H.sup.+]=658.25 calculated for
C.sub.34H.sub.39N.sub.7O.sub.5S=657.79
EXAMPLE 43
N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-dihydro-1H-indol-3-yl]-4-(4-propylpiperazin-1-yl)piperidine-1-carbo-
xamide
[0229] ESI-MS [M+H.sup.+]=732.3 calculated for
C.sub.37H.sub.45N.sub.7O.sub.7S=731.88
EXAMPLE 55
N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-dihydro-1H-indol-3-yl]-4-piperazin-1-ylpiperidine-1-carboxamide
55a) tert-Butyl
4-[1-({[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-y-
l)-2-oxo-2,3-dihydro-1H-indol-3-yl]amino}carbonyl)piperidin-4-yl]pipiperaz-
ine-1-carboxylate
[0230] 100 mg (0.16 mmol) of
phenyl[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)2-oxo-2,3-dihydro-1H-indol-3-yl]carbamate (prepared according to
Example 1, process steps 1a) to 1f)) were initially charged in 8 ml
of anhydrous tetrahydrofuran (dried over molecular sieve), and 65.8
mg (0.24 mmol) of tert-butyl
4-piperidin-4-ylpiperazine-1-carboxylate were added. The mixture
was then stirred at room temperature overnight. The progress of the
reaction was monitored by TLC (silica gel, CH.sub.2Cl.sub.2/MeOH
9:1) and LCMS (RP, mobile phases acetonitrile/water and 0.01% TFA).
The solvent was removed under reduced pressure, and the residue was
taken up in dichloromethane and extracted with 2 N aqueous sodium
hydroxide solution (1.times.). The combined organic phases were
dried over magnesium sulphate and filtered, and the solvent was
removed under reduced pressure. The crude mixture was purified by
column chromatography (5 g NP-SiO.sub.2 cartridge, Chromabond)
using dichloromethane/methanol in a ratio of 98:2 as mobile phase.
This gave 55.3 mg (0.07 mmol, 43%) of the desired product, which
was directly used in the next reaction step for Boc
deprotection.
[0231] ESI-MS [M+H.sup.+]=790.30 calculated for
C.sub.39H.sub.47N.sub.7O.sub.9S=789.91
55b)
N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-piperazin-1-ylpiperidine-1-carboxamid-
e
[0232] 55.3 mg (0.07 mmol) of tert-butyl
4-[1-({[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-y-
l)-2-oxo-2,3,-dihydro-1H-indol-3-yl]amino}carbonyl)piperidin-4-yl]piperazi-
ne-1-carboxylate were initially charged in 4 ml of methanol, and
1.0 ml of 5-6 M hydrochloric acid in isopropanol was added. The
mixture was stirred at room temperature. The progress of the
reaction was monitored by TLC (silica gel, CH.sub.2Cl.sub.2/MeOH
9:1). After complete conversion, the alcoholic solvent residues
were removed, and the residue was taken up in dichloromethane and,
using 1 N aqueous sodium hydroxide solution, adjusted by extraction
to pH 9. The organic phase was separated from the aqueous phase,
and the aqueous phase was reextracted with dichloromethane
(2.times.). The combined organic phase was dried over magnesium
sulphate, and the solvent was removed under reduced pressure. The
residue was crystallized from diethyl ether. Alternatively, the
residue can also be purified either by conventional column
chromatography on a normal phase (NP-SiO.sub.2 cartridge,
Chromabond) using dichloromethane/methanol as mobile phases or by
preparative HPLC (RP, mobile phases acetonitrile/water, 0.01% TFA).
After crystallization, 15.9 mg (0.023 mmol, 33%) of
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo-2,3-dihydro-1H-indol-3-yl]-4-piperazin-1-ylpiperidine-1-carboxamide
were isolated.
[0233] ESI-MS [M+H.sup.+]=690.45 calculated for
C.sub.34H.sub.39N.sub.7O.sub.7S=689.80
EXAMPLES 25 TO 30 AND 56 TO 60 AND 85 TO 90
[0234] The compounds according to Examples 25 to 30 and 56 to 60
and 85 to 90 can also be prepared in a manner analogous to the
preparation procedures according to Examples 1, 5, 31, 37 and/or 55
using the appropriate starting materials.
EXAMPLE 25
N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-dihydro-1H-indol-3-yl]-4-piperidin-4-ylpiperazine-1-carboxamide
bis(trifluoroacetate)
[0235] ESI-MS [M+H.sup.+]=690.15 calculated for
C.sub.34H.sub.39N.sub.7O.sub.7S=689.80
EXAMPLE 85
N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-dihydro-1H-indol-3-yl]-4,4'-bipiperidine-1-carboxamide
bis(trifluoroacetate)
[0236] ESI-MS [M+H.sup.+]=689.25 calculated for
C.sub.35H.sub.40N.sub.6O.sub.7S=688.81
[0237] In the compounds (I) according to the invention, the
substituent R7 can, according to synthesis scheme 1 or 2, also be
introduced subsequently by reductive amination, which is to be
illustrated in an exemplary manner using Examples 61 and 67:
EXAMPLE 61
N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-dihydro-1H-indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carboxamide
[0238] 100 mg (0.138 mmol) of
4-[1-({[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-y-
l)-2-oxo-2,3-dihydro-1H-indol-3-yl]amino}carbonyl)piperidin-4-yl]piperidin-
ium chloride (corresponds to the chloride salt of Example 85)
(prepared according to Example 1, process steps 1a) to 1f) and
Example 55, process steps 55a) to 55b)) were initially introduced
in 10 ml of dichloromethane. 20 .mu.l (0.207 mmol) of aqueous
formaldehyde solution (37% strength) were added, and the reaction
mixture was stirred for 5 minutes. The solution became slightly
turbid. 98 mg (0.69 mmol) of sodium sulphate and 20 .mu.l (0.279
mmol) of glacial acetic acid were added, and the mixture was
stirred for 1.5 h. 48.7 mg (0.207 mmol) of the hydrogenation
reagent sodium acetoxyborohydride were introduced a little at a
time, and after 15 minutes the reaction mixture became clear and
then soon turbid again. The mixture was stirred at room temperature
overnight and warmed to 40.degree. C. for another hour. The
reaction mixture was initially diluted with 30 ml of
dichloromethane and then extracted with saturated sodium
bicarbonate solution (3.times.). The combined organic phases were
dried over magnesium sulphate and filtered, and the solvent was
evaporated under reduced pressure. What was isolated were 75 mg of
crude product which was purified by a preparative HPLC on a
Chromolith column (RP-18e, from Merck, mobile phases
acetonitrile/water, 0.01% acetic acid). What was isolated were 5 mg
(0.007 mmol, 5%) of the desired
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin--
3-yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carbo-
xamide (proportionally present as acetate salt).
[0239] ESI-MS [M+H.sup.+]=703.2 calculated for
C.sub.36H.sub.42N.sub.6O.sub.7S=702.83
EXAMPLE 67
N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-dihydro-1H-indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carboxamide
trifluoroacetate
[0240] ESI-MS [M+H.sup.+]=717.30 calculated for
C.sub.37H.sub.44N.sub.6O.sub.7S=716.86
[0241] RACEMATE RESOLUTION of the racemic compounds according to
EXAMPLES 1 to 90:
[0242] In an exemplary manner, using Example 1, the separation of
the racemates into its enantiomers (Example 1A and 1 B) by
separation on a preparative chiral column is shown:
[0243] A.) RACEMATE RESOLUTION of the racemic compound according to
EXAMPLE 1:
[0244] 100 mg (0.14 mmol) of the racemic
N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2--
oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carb-
oxamide (EXAMPLE 1) were separated on a chiral preparative column
(Chiralcell OD, flow rate 55 ml/min) using n-heptane/ethanol
(700:300) as eluent. The enantiomer which eluted first, having a
positive optical rotation (Example 1A), could be isolated in a
yield of 19 mg (0.03 mmol, 19%) and the enantiomer which followed,
having a negative optical rotation (Example 1 B), could be isolated
in a yield of 8 mg (0.01 mmol, 8%).
EXAMPLE 1A
(+)-N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-c-
arboxamide
[0245] ESI-MS [M+H.sup.+]=704.25 calculated for
C.sub.35H.sub.41N.sub.7O.sub.7S=703.82
[0246] HPLC (Chiralcel OD 0.46 cm.times.25 cm; n-heptane/ethanol
7:3) R.sub.f=9.04 min
[0247] Optical rotation .alpha. (22.degree. C., 589 nm, CHCl.sub.3,
1 mg/ml)=dextrorotatory
[0248] .sup.1H-NMR ([D6]-DMSO, 500 MHz) .delta. [ppm]=8.13 (dd, 1H,
J=1.6 Hz, J=4.9 Hz), 7.89 (d, 1H, J=8.9 Hz), 7.88 (d, 1H, J=8.6
Hz), 7.82 (dd, 1H, J=1.7 Hz, J=8.6 Hz), 7.72 (dd, 1H, J=1.5 Hz,
J=7.7 Hz), 7.68 (d, 1H, J=1.6 Hz), 7.65 (s, 1H), 7.02 (dd, 1H,
J=4.9 Hz, J=7.6 Hz), 6.69 (dd, 1H, J=2.2 Hz, J=8.9 Hz), 6.66 (d,
1H, J=2.1 Hz), 4.17 (m, 2H), 3.86 (s, 3H), 3.45 (s, 3H), 3.21 (m,
4H), 2.77 (m, 2H, J=11.0 Hz), 2.34 (m, 4H), 2.12 (m, 4H), 1.82 (m,
2H, J=10.9 Hz), 1.64 (m, 2H, J=10.8 Hz), 1.37 (m, 2H), 1.08 (t, 3H,
J=7.0 Hz).
EXAMPLE 1B
(-)-N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-c-
arboxamide
[0249] ESI-MS [M+H.sup.+]=704.25 calculated for
C.sub.35H.sub.41N.sub.7O.sub.7S=703.82
[0250] HPLC (Chiralcel OD 0.46 cm.times.25 cm; n-heptane/ethanol
7:3) R.sub.f=25.73 min
[0251] Optical rotation .alpha. (22.degree. C., 589 nm, CHCl.sub.3,
1 mg/ml)=laevorotatory
[0252] .sup.1H-NMR ([D6]-DMSO, 500 MHz) .delta. [ppm]=8.13 (dd, 1H,
J=1.2 Hz, J=4.7 Hz), 7.88 (d, 1H, J=8.9 Hz), 7.87 (d, 1H, J=8.5
Hz), 7.81 (dd, 1H, J=1.5 Hz, J=8.5 Hz), 7.72 (dd, 1H, J=1.1 Hz,
J=7.6 Hz), 7.68 (s, 1H), 7.64 (s, 1H), 7.01 (dd, 1H, J=4.9 Hz,
J=7.6 Hz), 6.69 (dd, 1H, J=1.9 Hz, J=9.0 Hz), 6.66 (d, 1H, J=1.9
Hz), 4.16 (m, 2H), 3.85 (s, 3H), 3.45 (s, 3H), 3.20 (m, 4H), 2.77
(m, 2H, J=11.5 Hz), 2.34 (m, 4H), 2.12 (m, 4H), 1.82 (m, 2H, J=11.3
Hz), 1.64 (m, 2H, J=11.5 Hz), 1.37 (m, 2H), 1.07 (t, 3H, J=7.0
Hz).
[0253] B.) RACEMATE RESOLUTION of the racemic compound according to
EXAMPLE 31:
[0254]
N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3--
yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine--
1-carboxamide (EXAMPLE 31) was separated on a chiral preparative
column (Chiralcell OD, flow rate 55 ml/min) using n-heptane/ethanol
(700:300) as eluent. The enantiomer which eluted first has a
positive optical rotation (Example 31A), and the enantiomer which
followed had a negative optical rotation (Example 31 B).
EXAMPLE 31A
(+)-N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-c-
arboxamide
[0255] ESI-MS [M+H.sup.+]=704.80 calculated for
C.sub.35H.sub.41N.sub.7O.sub.7S=703.82
[0256] HPLC (Chiralcel OD 0.46 cm.times.25 cm; n-heptane/ethanol
7:3) R.sub.f=9.60 min
[0257] Optical rotation .alpha. (22.degree. C., 589 nm, CHCl.sub.3,
1 mg/ml)=dextrorotatory
[0258] .sup.1H-NMR ([D6]-DMSO, 500 MHz) .delta. [ppm]=8.12 (dd, 1H,
J=1.6 Hz, J=4.8 Hz), 7.87 (d, 1H, J=8.5 Hz), 7.86 (d, 1H, J=8.8
Hz), 7.81 (dd, 1H, J=1.7 Hz, J=8.6 Hz), 7.73 (dd, 1H, J=1.5 Hz,
J=7.7 Hz), 7.69 (s, 1H), 7.67 (d, 1H, J=1.5 Hz), 7.02 (dd, 1H,
J=4.9 Hz, J=7.6 Hz), 6.67 (dd, 1H, J=2.2 Hz, J=8.9 Hz), 6.65 (d,
1H, J=2.1 Hz), 4.14 (m, 2H), 3.83 (s, 3H), 3.80 (m, 2H), 3.42 (s,
3H), 2.60 (m, 2H), 2.39-2.10 (m, 9H), 2.10 (s, 3H), 1.60 (m, 2H),
1.12 (m, 2H), 1.06 (t, 3H, J=7.0 Hz).
EXAMPLE 31B
(-)-N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-c-
arboxamide
[0259] ESI-MS [M+H.sup.+]=704.80 calculated for
C.sub.35H.sub.41N.sub.7O.sub.7S=703.82
[0260] HPLC (Chiralcel OD 0.46 cm.times.25 cm; n-heptane/ethanol
7:3) R.sub.f=34.31 min
[0261] Optical rotation .alpha. (22.degree. C., 589 nm, CHCl.sub.3,
1 mg/ml)=laevorotatory
[0262] .sup.1H-NMR ([D6]-DMSO, 500 MHz) .delta. [ppm]=8.12 (dd, 1H,
J=1.6 Hz, J=4.9 Hz), 7.86 (d, 1H, J=8.7 Hz), 7.85 (d, 1H, J=8.8
Hz), 7.81 (dd, 1H, J=1.6 Hz, J=8.6 Hz), 7.72 (dd, 1H, J=1.4 Hz,
J=7.6 Hz), 7.69 (s, 1H), 7.67 (d, 1H, J=1.6 Hz), 7.02 (dd, 1H,
J=4.9 Hz, J=7.6 Hz), 6.67 (dd, 1H, J=2.2 Hz, J=8.9 Hz), 6.64 (d,
1H, J=2.0 Hz), 4.13 (m, 2H), 3.83 (s, 3H), 3.80 (m, 2H), 3.42 (s,
3H), 2.60 (m, 2H), 2.42-2.10 (m, 9H), 2.10 (s, 3H), 1.60 (m, 2H),
1.12 (m, 2H), 1.06 (t, 3H, J=7.0 Hz).
[0263] C.) RACEMATE RESOLUTION of the racemic compound according to
EXAMPLE 37:
[0264]
N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3--
yl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-
-carboxamide (EXAMPLE 37) was separated on a chiral preparative
column (Chiralcell OD, flow rate 55 ml/min) using n-heptane/ethanol
(700:300) as eluent. The enantiomer which eluted first had a
positive optical rotation (Example 37A), and the enantiomer which
followed had a negative optical rotation (Example 37B).
EXAMPLE 37A
(+)-N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-ca-
rboxamide
[0265] ESI-MS [M+H.sup.+]=718.30 calculated for
C.sub.36H.sub.43F.sub.3N.sub.7O.sub.7S=717.85
[0266] HPLC (Chiralcel OD 0.46 cm.times.25 cm; n-heptane/ethanol
7:3) R.sub.f=7.29 min
[0267] Optical rotation .alpha. (22.degree. C., 589 nm, CHCl.sub.3,
1 mg/ml)=dextrorotatory
[0268] .sup.1H-NMR ([D6]-DMSO, 500 MHz) .delta. [ppm]=8.13 (dd, 1H,
J=1.7 Hz, J=4.9 Hz), 7.89 (d, 1H, J=8.6 Hz), 7.88 (d, 1H, J=8.8
Hz), 7.82 (dd, 1H, J=1.8 Hz, J=8.6 Hz), 7.72 (dd, 1H, J=1.7 Hz,
J=7.7 Hz), 7.69 (d, 1H, J=1.7 Hz), 7.67 (s, 1H), 7.02 (dd, 1H,
J=4.9 Hz, J=7.7 Hz), 6.69 (dd, 1H, J=2.2 Hz, J=8.9 Hz), 6.66 (d,
1H, J=2.2 Hz), 4.18 (m, 2H), 3.85 (s, 3H), 3.81 (m, 2H), 3.44 (s,
3H), 2.62 (m, 2H), 2.42-2.24 (m, 11H), 1.62 (m, 2H), 1.15 (m, 2H),
1.09 (t, 3H, J=7.1 Hz), 0.96 (t, 3H, J=7.2 Hz).
EXAMPLE 37B
(-)-N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-ca-
rboxamide
[0269] ESI-MS [M+H.sup.+]=718.25 calculated for
C.sub.36H.sub.43F.sub.3N.sub.7O.sub.7S=717.85
[0270] HPLC (Chiralcel OD 0.46 cm.times.25 cm; n-heptane/ethanol
7:3) R.sub.f=12.41 min
[0271] Optical rotation .alpha. (22.degree. C., 589 nm, CHCl.sub.3,
1 mg/ml)=laevorotatory
[0272] .sup.1H-NMR ([D6]-DMSO, 500 MHz) .delta. [ppm]=8.12 (dd, 1H,
J=1.6 Hz, J=4.9 Hz), 7.88 (d, 1H, J=8.5 Hz), 7.87 (d, 1H, J=8.8
Hz), 7.80 (dd, 1H, J=1.7 Hz, J=8.6 Hz), 7.71 (dd, 1H, J=1.5 Hz,
J=7.7 Hz), 7.68 (d, 1H, J=1.5 Hz), 7.66 (s, 1H), 7.00 (dd, 1H,
J=4.9 Hz, J=7.6 Hz), 6.67 (dd, 1H, J=2.2 Hz, J=8.9 Hz), 6.65 (d,
1H, J=2.1 Hz), 4.16 (m, 2H), 3.84 (s, 3H), 3.80 (m, 2H), 3.44 (s,
3H), 2.61 (m, 2H), 2.41-2.23 (m, 11H), 1.60 (m, 2H), 1.14 (m, 2H),
1.08 (t, 3H, J=7.1 Hz), 0.95 (t, 3H, J=7.2 Hz).
[0273] D.) RACEMATE RESOLUTION of the racemic compounds 2 to 30, 21
to 36 and 38 to 90:
[0274] In a manner analogous to the racemate resolutions of the
racemic compounds 1, 31 and 37, it is possible to carry out the
separation of the racemates 2 to 30, 32 to 36 and 38 to 90 give the
corresponding (+)-enantiomers 2A, 3A, 4A, 5A, 6A, 7A, 8A, 9A, 10A,
11A, 12A, 13A, 14A, 15A, 16A, 17A, 18A, 19A, 20A, 21A, 22A, 23A,
24A, 25A, 26A, 27A, 28A, 29A, 30A and 32A, 33A, 34A, 35A and 38A,
39A, 40A, 41A, 42A, 43A, 44A, 45A, 46A, 47A, 48A, 49A, 50A, 51A,
52A, 53A, 54A, 55A, 56A, 57A, 58A, 59A, 60A, 61A, 62A, 63A, 64A,
65A, 66A, 67A, 68A, 69A, 70A, 71A, 72A, 73A, 74A, 75A, 76A, 77A,
78A, 79A, 80A, 81A, 82A, 83A, 84A, 85A, 86A, 87A, 88A, 89A and 90A
and the corresponding (-)-enantiomers 2B, 3B, 4B, 5B, 6B, 7B, 8B,
9B, 10B, 11 B, 12B, 13B, 14B, 15B, 16B, 17B, 18B, 19B, 20B, 21B,
22B, 23B, 24B, 25B, 26B, 27B, 28B, 29B, 30B and 32B, 33B, 34B, 35B
and 38B, 39B, 40B, 41B, 42B, 43B, 44B, 45B, 46B, 47B, 48B, 49B,
50B, 51B, 52B, 53B, 54B, 55B, 56B, 57B, 58B, 59B, 60B, 61B, 62B,
63B, 64B, 65B, 66B, 67B, 68B, 69B, 70B, 71B, 72B, 73B, 74B, 75B,
76B, 77B, 78B, 79B, 80B, 81B, 82B, 83B, 84B, 85B, 86B, 87B, 88B,
89B and 90B.
[0275] The enantiomers A and B can also be prepared using
enantiomerically pure precursors and intermediates, for example
analogously to synthesis schemes 1 or 2, preferably via synthesis
scheme 1. The separation of the racemic mixture into the
(+)-enantiomers and (-)-enantiomers can be carried out by chiral
preparative chromatography, preferably via the corresponding amine
building block VI.
EXAMPLE 7B
(-)-N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-ethylpiperidin-4-yl)piperazine-1-ca-
rboxamide trifluoroacetate
[0276] ESI-MS [M+H.sup.+]=718.25 calculated for
C.sub.36H.sub.43N.sub.7O.sub.7S=717.85
EXAMPLE 40B
(-)-N-[5-Cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dihy-
dro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidin-1-carboxamide
[0277] ESI-MS [M+H.sup.+]=658.25 calculated for
C.sub.34H.sub.39N.sub.7O.sub.5S=657.79
EXAMPLE 61B
(-)-N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl)-3-(2-ethoxypyridin-3-yl)-
-2-oxo-2,3-dihydro-1H-indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carboxamid-
e trifluoroacetate
[0278] ESI-MS [M+H.sup.+]=703.30 calculated for
C.sub.36H.sub.42N.sub.6O.sub.7S=702.83
[0279] .sup.1H-NMR ([D6]-DMSO, 500 MHz) .delta. [ppm]=9.26 (1H,
protonation of TFA), 8.12 (dd, 1H, J=1.7 Hz, J=4.9 Hz), 7.87 (dd,
2H, J=1.3 Hz, J=8.7 Hz), 7.80 (dd, 1H, J=1.8 Hz, J=8.5 Hz), 7.80
(m, 2H), 7.66 (s, 1H), 7.00 (dd, 1H, J=4.9 Hz, J=7.6 Hz), 6.68 (dd,
1H, J=2.2 Hz, J=8.9 Hz), 6.65 (d, 1H, J=2.1 Hz), 4.16 (m, 2H), 3.85
(s, 6H), 3.44-3.41 (m, 5H), 2.85 (m, 2H), 2.73 (m, 2H), 2.57 (m,
2H), 1.81 (m, 2H), 1.55 (m, 2H), 1.34-1.22 (m, 4H), 1.08 (t, 3H,
J=7.0 Hz), 0.92 (m, 2H).
EXAMPLE 67B
(-)-N-[5-Cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-
-2-oxo-2,3-dihydro-1H-indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carboxamide
trifluoroacetate
[0280] ESI-MS [M+H.sup.+]=717.35 calculated for
C.sub.37H.sub.44N.sub.6O.sub.7S=716.86
[0281] The amines of the general formula X can be prepared
according to synthesis scheme 1 or 2 by reductive amination.
Hereinbelow, this is shown using the preparation of the amine
compound 1-ethyl-4-piperidin-4-ylpiperazine as an example:
EXAMPLE 91
1-Ethyl-4-piperidin-4-ylpiperazine
91a) tert-Butyl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate
[0282] With ice-cooling, 29.2 g (256 mmol) of N-ethylpiperazine and
50.0 g (256 mmol) of tert-butyl 4-oxopiperidine-1-carboxylate
(corresponds to 1-Boc-4-piperidone) were initially charged in 800
ml of ethanol and 15.4 g (256 mmol) of glacial acetic acid were
added. A little at a time, 16.1 g (256 mmol) of sodium
acetoxyborohydride was then added to the cooled reaction mixture.
Initially, a slight evolution of gas and, after 2/3 of the reducing
agent had been added, foaming could be observed. The reaction
mixture was stirred at room temperature overnight. For work-up, 200
ml of 2 N aqueous sodium hydroxide solution were added with cooling
to the reaction solution, the solvent ethanol was distilled off and
the reaction mixture which remained was diluted with water. The
mixture was extracted with diethyl ether (2.times.) and washed with
saturated sodium chloride solution (1.times.), the combined organic
phases were dried over magnesium sulphate and filtered and the
solvent was removed under reduced pressure. The desired product was
obtained as a yellow oil which was subsequently chromatographed on
a 4 I Nutsche filter filled with silica gel, using dichloromethane
and 10% methanol as eluents. This gave a total of 40 g (135 mmol,
53%) of tert-butyl
4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate.
91 b) 1-Ethyl-4-piperidin-4-ylpiperazine as Chloride Salt
[0283] To remove the protective groups, 40 g (135 mmol) of the
tert-butyl 4-(4-ethylpiperazin-1-yl)piperidine-1-carboxylate were
initially charged in 200 ml of methanol and 1.8 I of
dichloromethane, and 100 ml 5-6 M HCl solution in isopropanol were
added. The solution became a suspension, and a slight evolution of
gas could be observed. The reaction mixture was stirred at
40.degree. C. (water bath temperature) for one hour and at room
temperature over the weekend. For complete deprotection to the
desired product, another 50 ml of the 5-6 M HCl solution in
isopropanol were added, and the mixture was stirred at 40.degree.
C. The dichloromethane was distilled off on a rotary evaporator,
and another 200 ml of methanol and 30 ml of the 5-6 M HCl solution
in isopropanol were added. After one hour of stirring under reflux,
a white suspension formed with strong evolution of gas.
Subsequently, a low-viscosity suspension was fomed, which was
cooled to room temperature. The precipitate was filtered off with
suction and washed with methanol and diethyl ether. After drying,
36 g (117 mmol, 87%) of 1-ethyl-4-piperidin-4-ylpiperazine were
isolated as chloride salt.
[0284] .sup.1H-NMR (D.sub.2O, 400 MHz) .delta. [ppm]=3.74-3.47 (m,
11 H), 3.28 (q, 2H, J=7.3 Hz), 3.06 (dt, 2H, J=2.2 Hz, J=13.2 Hz),
2.38 (m, 2H, J=13.6 Hz), 1.89 (dq, 2H, J=4.1 Hz, J=13.3 Hz), 1.30
(t, 3H, J=7.3 Hz).
[0285] The chemical structures of the compounds according to
Examples 1 to 90 (racemate) and the corresponding dextrorotatory
(+)-enantiomers (Examples Nos. 1 to 90 with the appended letter "A"
such as, for example, 1A, 2A, etc. . . . ) and the corresponding
laevorotatory (-)-enantiomers (Example Nos. 1 to 90 with the
appended letter "B", such as, for example, 1B, 2B, etc. . . . ) are
shown in Table 2 below:
##STR00007##
TABLE-US-00002 TABLE 2 Compounds of the general formula (Ib) where
the radicals R5, R6, R7, X2 and X3 have the meanings mentioned
below (in each case per row): Exp. IUPAC Name No. X2 X3 R5 R6 R7
(according to ACD-Labs Version 8.00 release product version 8.05) 1
N CH methoxy methoxy methyl
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-ca-
rboxamide 1A N CH methoxy methoxy methyl
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-ca-
rboxamide 1B N CH methoxy methoxy methyl
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-ca-
rboxamide 2 N CH methoxy H methyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-methylpiperidin-4-yl)piperazine-1-carbox-
amide 2A N CH methoxy H methyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-methylpiperidin-4-yl)piperazine-1-carbox-
amide 2B N CH methoxy H methyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-methylpiperidin-4-yl)piperazine-1-carbox-
amide 3 N CH ethoxy H methyl
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-
dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carbox-
amide 3A N CH ethoxy H methyl
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carbox-
amide 3B N CH ethoxy H methyl
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carbox-
amide 4 N CH H H methyl
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H-
indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carboxamide 4A N
CH H H methyl
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H-
indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carboxamide 4B N
CH H H methyl
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H-
indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine-1-carboxamide 5 N
CH H methoxy methyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-methylpiperidin-4-yl)piperazine-1-carbox-
amide 5A N CH H methoxy methyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-methylpiperidin-4-yl)piperazine-1-carbox-
amide 5B N CH H methoxy methyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-methylpiperidin-4-yl)piperazine-1-carbox-
amide 6 N CH ethoxy methoxy methyl
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazin-
e-1-carboxamide 6A N CH ethoxy methoxy methyl
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazin-
e-1-carboxamide 6B N CH ethoxy methoxy methyl
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2-
oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-methylpiperidin-4-yl)piperazine--
1-carboxamide 7 N CH methoxy methoxy ethyl
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(1-ethylpiperidin-4-yl)piperazine-1-car-
boxamide 7A N CH methoxy methoxy ethyl
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(1-ethylpiperidin-4-yl)piperazine-1-car-
boxamide 7B N CH methoxy methoxy ethyl
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(1-ethylpiperidin-4-yl)piperazine-1-car-
boxamide 8 N CH methoxy H ethyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-ethylpiperidin-4-yl)piperazine-1-carboxa-
mide 8A N CH methoxy H ethyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-ethylpiperidin-4-yl)piperazine-1-carboxa-
mide 8B N CH methoxy H ethyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-ethylpiperidin-4-yl)piperazine-1-carboxa-
mide 9 N CH ethoxy H ethyl
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-
dihydro-1H-indol-3-yl]-4-(1-ethylpiperidin-4-yl)piperazine-1-carboxa-
mide 9A N CH ethoxy H ethyl
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-(1-ethylpiperidin-4-yl)piperazine-1-carboxa-
mide 9B N CH ethoxy H ethyl
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-(1-ethylpiperidin-4-yl)piperazine-1-carboxa-
mide 10 N CH H H ethyl
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H-
indol-3-yl]-4-(1-ethylpiperidin-4-yl)piperazine-1-carboxamide 10A N
CH H H ethyl
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H-
indol-3-yl]-4-(1-ethylpiperidin-4-yl)piperazine-1-carboxamide 10B N
CH H H ethyl
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H-
indol-3-yl]-4-(1-ethylpiperidin-4-yl)piperazine-1-carboxamide 11 N
CH H methoxy ethyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-ethylpiperidin-4-yl)piperazine-1-carboxa-
mide 11A N CH H methoxy ethyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-ethylpiperidin-4-yl)piperazine-1-carboxa-
mide 11B N CH H methoxy ethyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-ethylpiperidin-4-yl)piperazine-1-carboxa-
mide 12 N CH ethoxy methoxy ethyl
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-ethylpiperidin-4-yl)piperazine-
-1-carboxamide 12A N CH ethoxy methoxy ethyl
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-ethylpiperidin-4-yl)piperazine-
-1-carboxamide 12B N CH ethoxy methoxy ethyl
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2-
oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-ethylpiperidin-4-yl)piperazine-1-
-carboxamide 13 N CH methoxy methoxy n-
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo- propyl
2,3-dihydro-1H-indol-3-yl]-4-(1-propylpiperidin-4-yl)piperazine-1-carboxa-
mide 13A N CH methoxy methoxy n-
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo- propyl
2,3-dihydro-1H-indol-3-yl]-4-(1-propylpiperidin-4-yl)piperazine-1-carboxa-
mide 13B N CH methoxy methoxy n-
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo- propyl
2,3-dihydro-1H-indol-3-yl]-4-(1-propylpiperidin-4-yl)piperazine-1-carboxa-
mide 14 N CH methoxy H n-
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3- propyl
dihydro-1H-indol-3-yl}-4-(1-propylpiperidin-4-yl)piperazine-1-carboxamide
14A N CH methoxy H n-
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3- propyl
dihydro-1H-indol-3-yl}-4-(1-propylpiperidin-4-yl)piperazine-1-carboxamide
14B N CH methoxy H n-
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3- propyl
dihydro-1H-indol-3-yl}-4-(1-propylpiperidin-4-yl)piperazine-1-carboxamide
15 N CH ethoxy H n-
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3- propyl
dihydro-1H-indol-3-yl]-4-(1-propylpiperidin-4-yl)piperazine-1-carboxamide
15A N CH ethoxy H n-
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3- propyl
dihydro-1H-indol-3-yl]-4-(1-propylpiperidin-4-yl)piperazine-1-carboxamide
15B N CH ethoxy H n-
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3- propyl
dihydro-1H-indol-3-yl]-4-(1-propylpiperidin-4-yl)piperazine-1-carboxamide
16 N CH H H n-
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H- propyl
indol-3-yl]-4-(1-propylpiperidin-4-yl)piperazine-1-carboxamide 16A
N CH H H n-
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- propyl
indol-3-yl]-4-(1-propylpiperidin-4-yl)piperazine-1-carboxamide 16B
N CH H H n-
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- propyl
indol-3-yl]-4-(1-propylpiperidin-4-yl)piperazine-1-carboxamide
17 N CH H methoxy n-
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3- propyl
dihydro-1H-indol-3-yl}-4-(1-propylpiperidin-4-yl)piperazine-1-carboxamide
17A N CH H methoxy n-
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3- propyl
dihydro-1H-indol-3-yl}-4-(1-propylpiperidin-4-yl)piperazine-1-carboxamide
17B N CH H methoxy n-
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3- propyl
dihydro-1H-indol-3-yl}-4-(1-propylpiperidin-4-yl)piperazine-1-carboxamide
18 N CH ethoxy methoxy n-
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)- propyl
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-propylpiperidin-4-yl)piperazine-1-c-
arboxamide 18A N CH ethoxy methoxy n-
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)- propyl
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-propylpiperidin-4-yl)piperazine-1-c-
arboxamide 18B N CH ethoxy methoxy n-
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2- propyl
oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-propylpiperidin-4-yl)piperazine-1-car-
boxamide 19 N CH methoxy methoxy isopropyl
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(1-isopropylpiperidin-4-yl)piperazine-1-
-carboxamide 19A N CH methoxy methoxy isopropyl
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(1-isopropylpiperidin-4-yl)piperazine-1-
-carboxamide 19B N CH methoxy methoxy isopropyl
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(1-isopropylpiperidin-4-yl)piperazine-1-
-carboxamide 20 N CH methoxy H isopropyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-isopropylpiperidin-4-yl)piperazine-1-car-
boxamide 20A N CH methoxy H isopropyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-isopropylpiperidin-4-yl)piperazine-1-car-
boxamide 20B N CH methoxy H isopropyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-isopropylpiperidin-4-yl)piperazine-1-car-
boxamide 21 N CH ethoxy H isopropyl
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-
dihydro-1H-indol-3-yl]-4-(1-isopropylpiperidin-4-yl)piperazine-1-car-
boxamide 21A N CH ethoxy H isopropyl
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-(1-isopropylpiperidin-4-yl)piperazine-1-car-
boxamide 21B N CH ethoxy H isopropyl
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-(1-isopropylpiperidin-4-yl)piperazine-1-car-
boxamide 22 N CH H H isopropyl
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H-
indol-3-yl]-4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxamide
22A N CH H H isopropyl
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H-
indol-3-yl]-4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxamide
22B N CH H H isopropyl
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H-
indol-3-yl]-4-(1-isopropylpiperidin-4-yl)piperazine-1-carboxamide
23 N CH H methoxy isopropyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-isopropylpiperidin-4-yl)piperazine-1-car-
boxamide 23A N CH H methoxy isopropyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-isopropylpiperidin-4-yl)piperazine-1-car-
boxamide 23B N CH H methoxy isopropyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(1-isopropylpiperidin-4-yl)piperazine-1-car-
boxamide 24 N CH ethoxy methoxy isopropyl
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-isopropylpiperidin-4-yl)pipera-
zine-1-carboxamide 24A N CH ethoxy methoxy isopropyl
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-isopropylpiperidin-4-yl)pipera-
zine-1-carboxamide 24B N CH ethoxy methoxy isopropyl
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2-
oxo-2,3-dihydro-1H-indol-3-yl]-4-(1-isopropylpiperidin-4-yl)piperazi-
ne-1-carboxamide 25 N CH methoxy methoxy H
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-piperidin-4-ylpiperazine-1-carboxamide
25A N CH methoxy methoxy H
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-piperidin-4-ylpiperazine-1-carboxamide
25B N CH methoxy methoxy H
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-piperidin-4-ylpiperazine-1-carboxamide
26 N CH methoxy H H
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-piperidin-4-ylpiperazine-1-carboxamide 26A
N CH methoxy H H
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-piperidin-4-ylpiperazine-1-carboxamide 26B
N CH methoxy H H
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-piperidin-4-ylpiperazine-1-carboxamide 27
N CH ethoxy H H
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-
dihydro-1H-indol-3-yl]-4-piperidin-4-ylpiperazine-1-carboxamide 27A
N CH ethoxy H H
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-piperidin-4-ylpiperazine-1-carboxamide 27B
N CH ethoxy H H
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-piperidin-4-ylpiperazine-1-carboxamide 28
N CH H H H
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H- indol-3-yl]-4-piperidin-4-ylpiperazine-1-carboxamide
28A N CH H H H
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- indol-3-yl]-4-piperidin-4-ylpiperazine-1-carboxamide 28B N
CH H H H
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- indol-3-yl]-4-piperidin-4-ylpiperazine-1-carboxamide 29 N
CH H methoxy H
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-piperidin-4-ylpiperazine-1-carboxamide 29A
N CH H methoxy H
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-piperidin-4-ylpiperazine-1-carboxamide 29B
N CH H methoxy H
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-piperidin-4-ylpiperazine-1-carboxamide 30
N CH ethoxy methoxy H
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-piperidin-4-ylpiperazine-1-carbox-
amide 30A N CH ethoxy methoxy H
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-piperidin-4-ylpiperazine-1-carbox-
amide 30B N CH ethoxy methoxy H
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2-
oxo-2,3-dihydro-1H-indol-3-yl]-4-piperidin-4-ylpiperazine-1-carboxam-
ide 31 CH N methoxy methoxy methyl
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-ca-
rboxamide 31A CH N methoxy methoxy methyl
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-ca-
rboxamide 31B CH N methoxy methoxy methyl
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-ca-
rboxamide 32 CH N methoxy H methyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-methylpiperazin-1-yl)piperidine-1-carbox-
amide 32A CH N methoxy H methyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-methylpiperazin-1-yl)piperidine-1-carbox-
amide 32B CH N methoxy H methyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-methylpiperazin-1-yl)piperidine-1-carbox-
amide 33 CH N ethoxy H methyl
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-
dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carbox-
amide 33A CH N ethoxy H methyl
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carbox-
amide 33B CH N ethoxy H methyl
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carbox-
amide 34 CH N H H methyl
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H-
indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carboxamide 34A
CH N H H methyl
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H-
indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carboxamide 34B
CH N H H methyl
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H-
indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine-1-carboxamide 35
CH N H methoxy methyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-methylpiperazin-1-yl)piperidine-1-carbox-
amide 35A CH N H methoxy methyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-methylpiperazin-1-yl)piperidine-1-carbox-
amide 35B CH N H methoxy methyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-methylpiperazin-1-yl)piperidine-1-carbox-
amide 36 CH N ethoxy methoxy methyl
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidin-
e-1-carboxamide 36A CH N ethoxy methoxy methyl
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidin-
e-1-carboxamide 36B CH N ethoxy methoxy methyl
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2-
oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-methylpiperazin-1-yl)piperidine--
1-carboxamide 37 CH N methoxy methoxy ethyl
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-car-
boxamide 37A CH N methoxy methoxy ethyl
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-car-
boxamide 37B CH N methoxy methoxy ethyl
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-car-
boxamide 38 CH N methoxy H ethyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxa-
mide 38A CH N methoxy H ethyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxa-
mide 38B CH N methoxy H ethyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxa-
mide 39 CH N ethoxy H ethyl
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-
dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxa-
mide 39A CH N ethoxy H ethyl
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxa-
mide 39B CH N ethoxy H ethyl
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxa-
mide 40 CH N H H ethyl
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H-
indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxamide 40A
CH N H H ethyl
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H-
indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxamide 40B
CH N H H ethyl
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H-
indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxamide 41 CH
N H methoxy ethyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxa-
mide 41A CH N H methoxy ethyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxa-
mide 41B CH N H methoxy ethyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-ethylpiperazin-1-yl)piperidine-1-carboxa-
mide 42 CH N ethoxy methoxy ethyl
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-
-1-carboxamide 42A CH N ethoxy methoxy ethyl
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-
-1-carboxamide 42B CH N ethoxy methoxy ethyl
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2-
oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-ethylpiperazin-1-yl)piperidine-1-
-carboxamide 43 CH N methoxy methoxy n-
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo- propyl
2,3-dihydro-1H-indol-3-yl]-4-(4-propylpiperazin-1-yl)piperidine-1-carboxa-
mide 43A CH N methoxy methoxy n-
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo- propyl
2,3-dihydro-1H-indol-3-yl]-4-(4-propylpiperazin-1-yl)piperidine-1-carboxa-
mide 43B CH N methoxy methoxy n-
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo- propyl
2,3-dihydro-1H-indol-3-yl]-4-(4-propylpiperazin-1-yl)piperidine-1-carboxa-
mide 44 CH N methoxy H n-
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3- propyl
dihydro-1H-indol-3-yl}-4-(4-propylpiperazin-1-yl)piperidine-1-carboxamide
44A CH N methoxy H n-
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3- propyl
dihydro-1H-indol-3-yl}-4-(4-propylpiperazin-1-yl)piperidine-1-carboxamide
44B CH N methoxy H n-
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3- propyl
dihydro-1H-indol-3-yl}-4-(4-propylpiperazin-1-yl)piperidine-1-carboxamide
45 CH N ethoxy H n-
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3- propyl
dihydro-1H-indol-3-yl]-4-(4-propylpiperazin-1-yl)piperidine-1-carboxamide
45A CH N ethoxy H n-
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3- propyl
dihydro-1H-indol-3-yl]-4-(4-propylpiperazin-1-yl)piperidine-1-carboxamide
45B CH N ethoxy H n-
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3- propyl
dihydro-1H-indol-3-yl]-4-(4-propylpiperazin-1-yl)piperidine-1-carboxamide
46 CH N H H n-
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H- propyl
indol-3-yl]-4-(4-propylpiperazin-1-yl)piperidine-1-carboxamide 46A
CH N H H n-
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- propyl
indol-3-yl]-4-(4-propylpiperazin-1-yl)piperidine-1-carboxamide 46B
CH N H H n-
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- propyl
indol-3-yl]-4-(4-propylpiperazin-1-yl)piperidine-1-carboxamide 47
CH N H methoxy n-
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3- propyl
dihydro-1H-indol-3-yl}-4-(4-propylpiperazin-1-yl)piperidine-1-carboxamide
47A CH N H methoxy n-
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3- propyl
dihydro-1H-indol-3-yl}-4-(4-propylpiperazin-1-yl)piperidine-1-carboxamide
47B CH N H methoxy n-
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3- propyl
dihydro-1H-indol-3-yl}-4-(4-propylpiperazin-1-yl)piperidine-1-carboxamide
48 CH N ethoxy methoxy n-
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)- propyl
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-propylpiperazin-1-yl)piperidine-1-c-
arboxamide 48A CH N ethoxy methoxy n-
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)- propyl
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-propylpiperazin-1-yl)piperidine-1-c-
arboxamide 48B CH N ethoxy methoxy n-
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2- propyl
oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-propylpiperazin-1-yl)piperidine-1-car-
boxamide 49 CH N methoxy methoxy isopropyl
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(4-isopropylpiperazin-1-yl)piperidine-1-
-carboxamide 49A CH N methoxy methoxy isopropyl
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(4-isopropylpiperazin-1-yl)piperidine-1-
-carboxamide 49B CH N methoxy methoxy isopropyl
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-(4-isopropylpiperazin-1-yl)piperidine-1-
-carboxamide 50 CH N methoxy H isopropyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-isopropylpiperazin-1-yl)piperidine-1-car-
boxamide 50A CH N methoxy H isopropyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-isopropylpiperazin-1-yl)piperidine-1-car-
boxamide 50B CH N methoxy H isopropyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-isopropylpiperazin-1-yl)piperidine-1-car-
boxamide 51 CH N ethoxy H isopropyl
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-
dihydro-1H-indol-3-yl]-4-(4-isopropylpiperazin-1-yl)piperidine-1-car-
boxamide 51A CH N ethoxy H isopropyl
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-(4-isopropylpiperazin-1-yl)piperidine-1-car-
boxamide 51B CH N ethoxy H isopropyl
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-(4-isopropylpiperazin-1-yl)piperidine-1-car-
boxamide 52 CH N H H isopropyl
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H-
indol-3-yl]-4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxamide
52A CH N H H isopropyl
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H-
indol-3-yl]-4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxamide
52B CH N H H isopropyl
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H-
indol-3-yl]-4-(4-isopropylpiperazin-1-yl)piperidine-1-carboxamide
53 CH N H methoxy isopropyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-isopropylpiperazin-1-yl)piperidine-1-car-
boxamide 53A CH N H methoxy isopropyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-isopropylpiperazin-1-yl)piperidine-1-car-
boxamide 53B CH N H methoxy isopropyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-(4-isopropylpiperazin-1-yl)piperidine-1-car-
boxamide 54 CH N ethoxy methoxy isopropyl
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-isopropylpiperazin-1-yl)piperi-
dine-1-carboxamide 54A CH N ethoxy methoxy isopropyl
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-isopropylpiperazin-1-yl)piperi-
dine-1-carboxamide 54B CH N ethoxy methoxy isopropyl
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2-
oxo-2,3-dihydro-1H-indol-3-yl]-4-(4-isopropylpiperazin-1-yl)piperidi-
ne-1-carboxamide 55 CH N methoxy methoxy H
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-piperazin-1-ylpiperidine-1-carboxamide
55A CH N methoxy methoxy H
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-piperazin-1-ylpiperidine-1-carboxamide
55B CH N methoxy methoxy H
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4-piperazin-1-ylpiperidine-1-carboxamide
56 CH N methoxy H H
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-piperazin-1-ylpiperidine-1-carboxamide 56A
CH N methoxy H H
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-piperazin-1-ylpiperidine-1-carboxamide 56B
CH N methoxy H H
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-piperazin-1-ylpiperidine-1-carboxamide 57
CH N ethoxy H H
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-
dihydro-1H-indol-3-yl]-4-piperazin-1-ylpiperidine-1-carboxamide 57A
CH N ethoxy H H
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-piperazin-1-ylpiperidine-1-carboxamide 57B
CH N ethoxy H H
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-4-piperazin-1-ylpiperidine-1-carboxamide 58
CH N H H H
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H- indol-3-yl]-4-piperazin-1-ylpiperidine-1-carboxamide
58A CH N H H H
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- indol-3-yl]-4-piperazin-1-ylpiperidine-1-carboxamide 58B
CH N H H H
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- indol-3-yl]-4-piperazin-1-ylpiperidine-1-carboxamide 59 CH
N H methoxy H
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-4-piperazin-1-ylpiperidine-1-carboxamide 59A
CH N H methoxy H
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-piperazin-1-ylpiperidine-1-carboxamide 59B
CH N H methoxy H
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-4-piperazin-1-ylpiperidine-1-carboxamide 60
CH N ethoxy methoxy H
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-piperazin-1-ylpiperidine-1-carbox-
amide 60A CH N ethoxy methoxy H
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4-piperazin-1-ylpiperidine-1-carbox-
amide 60B CH N ethoxy methoxy H
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2-
oxo-2,3-dihydro-1H-indol-3-yl]-4-piperazin-1-ylpiperidine-1-carboxam-
ide 61 CH CH methoxy methoxy methyl
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carboxamide
61A CH CH methoxy methoxy methyl
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carboxamide
61B CH CH methoxy methoxy methyl
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carboxamide
62 CH CH methoxy H methyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-1'-methyl-4,4'-bipiperidine-1-carboxamide
62A CH CH methoxy H methyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-1'-methyl-4,4'-bipiperidine-1-carboxamide
62B CH CH methoxy H methyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-1'-methyl-4,4'-bipiperidine-1-carboxamide 63
CH CH ethoxy H methyl
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-
dihydro-1H-indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carboxamide
63A CH CH ethoxy H methyl
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carboxamide
63B CH CH ethoxy H methyl
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carboxamide 64
CH CH H H methyl
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H- indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carboxamide
64A CH CH H H methyl
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carboxamide 64B
CH CH H H methyl
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carboxamide 65
CH CH H methoxy methyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-1'-methyl-4,4'-bipiperidine-1-carboxamide
65A CH CH H methoxy methyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-1'-methyl-4,4'-bipiperidine-1-carboxamide
65B CH CH H methoxy methyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-1'-methyl-4,4'-bipiperidine-1-carboxamide 66
CH CH ethoxy methoxy methyl
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carbo-
xamide 66A CH CH ethoxy methoxy methyl
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carbo-
xamide 66B CH CH ethoxy methoxy methyl
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2-
oxo-2,3-dihydro-1H-indol-3-yl]-1'-methyl-4,4'-bipiperidine-1-carboxa-
mide 67 CH CH methoxy methoxy ethyl
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carboxamide
67A CH CH methoxy methoxy ethyl
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carboxamide
67B CH CH methoxy methoxy ethyl
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carboxamide
68 CH CH methoxy H ethyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-1'-ethyl-4,4'-bipiperidine-1-carboxamide 68A
CH CH methoxy H ethyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-1'-ethyl-4,4'-bipiperidine-1-carboxamide 68B
CH CH methoxy H ethyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-1'-ethyl-4,4'-bipiperidine-1-carboxamide 69
CH CH ethoxy H ethyl
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-
dihydro-1H-indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carboxamide 69A
CH CH ethoxy H ethyl
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carboxamide 69B
CH CH ethoxy H ethyl
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carboxamide 70
CH CH H H ethyl
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H- indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carboxamide
70A CH CH H H ethyl
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carboxamide 70B
CH CH H H ethyl
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carboxamide 71 CH
CH H methoxy ethyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-1'-ethyl-4,4'-bipiperidine-1-carboxamide 71A
CH CH H methoxy ethyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-1'-ethyl-4,4'-bipiperidine-1-carboxamide 71B
CH CH H methoxy ethyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-1'-ethyl-4,4'-bipiperidine-1-carboxamide 72
CH CH ethoxy methoxy ethyl
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carbox-
amide 72A CH CH ethoxy methoxy ethyl
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carbox-
amide 72B CH CH ethoxy methoxy ethyl
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2-
oxo-2,3-dihydro-1H-indol-3-yl]-1'-ethyl-4,4'-bipiperidine-1-carboxam-
ide 73 CH CH methoxy methoxy n-
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo- propyl
2,3-dihydro-1H-indol-3-yl]-1'-propyl-4,4'-bipiperidine-1-carboxamide
73A CH CH methoxy methoxy n-
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo- propyl
2,3-dihydro-1H-indol-3-yl]-1'-propyl-4,4'-bipiperidine-1-carboxamide
73B CH CH methoxy methoxy n-
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo- propyl
2,3-dihydro-1H-indol-3-yl]-1'-propyl-4,4'-bipiperidine-1-carboxamide
74 CH CH methoxy H n-
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3- propyl
dihydro-1H-indol-3-yl}-1'-propyl-4,4'-bipiperidine-1-carboxamide
74A CH CH methoxy H n-
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3- propyl
dihydro-1H-indol-3-yl}-1'-propyl-4,4'-bipiperidine-1-carboxamide
74B CH CH methoxy H n-
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3- propyl
dihydro-1H-indol-3-yl}-1'-propyl-4,4'-bipiperidine-1-carboxamide 75
CH CH ethoxy H n-
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3- propyl
dihydro-1H-indol-3-yl]-1'-propyl-4,4'-bipiperidine-1-carboxamide
75A CH CH ethoxy H n-
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3- propyl
dihydro-1H-indol-3-yl]-1'-propyl-4,4'-bipiperidine-1-carboxamide
75B CH CH ethoxy H n-
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3- propyl
dihydro-1H-indol-3-yl]-1'-propyl-4,4'-bipiperidine-1-carboxamide 76
CH CH H H n-
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H- propyl
indol-3-yl]-1'-propyl-4,4'-bipiperidine-1-carboxamide 76A CH CH H H
n-
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- propyl
indol-3-yl]-1'-propyl-4,4'-bipiperidine-1-carboxamide 76B CH CH H H
n-
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- propyl
indol-3-yl]-1'-propyl-4,4'-bipiperidine-1-carboxamide 77 CH CH H
methoxy n-
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3- propyl
dihydro-1H-indol-3-yl}-1'-propyl-4,4'-bipiperidine-1-carboxamide
77A CH CH H methoxy n-
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3- propyl
dihydro-1H-indol-3-yl}-1'-propyl-4,4'-bipiperidine-1-carboxamide
77B CH CH H methoxy n-
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3- propyl
dihydro-1H-indol-3-yl}-1'-propyl-4,4'-bipiperidine-1-carboxamide 78
CH CH ethoxy methoxy n-
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)- propyl
2-oxo-2,3-dihydro-1H-indol-3-yl]-1'-propyl-4,4'-bipiperidine-1-carboxamid-
e 78A CH CH ethoxy methoxy n-
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)- propyl
2-oxo-2,3-dihydro-1H-indol-3-yl]-1'-propyl-4,4'-bipiperidine-1-carboxamid-
e 78B CH CH ethoxy methoxy n-
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2- propyl
oxo-2,3-dihydro-1H-indol-3-yl]-1'-propyl-4,4'-bipiperidine-1-carboxamide
79 CH CH methoxy methoxy isopropyl
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-1'-isopropyl-4,4'-bipiperidine-1-carboxam-
ide 79A CH CH methoxy methoxy isopropyl
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-1'-isopropyl-4,4'-bipiperidine-1-carboxam-
ide 79B CH CH methoxy methoxy isopropyl
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-1'-isopropyl-4,4'-bipiperidine-1-carboxam-
ide 80 CH CH methoxy H isopropyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-1'-isopropyl-4,4'-bipiperidine-1-carboxamide
80A CH CH methoxy H isopropyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-1'-isopropyl-4,4'-bipiperidine-1-carboxamide
80B CH CH methoxy H isopropyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-1'-isopropyl-4,4'-bipiperidine-1-carboxamide
81 CH CH ethoxy H isopropyl
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3-
dihydro-1H-indol-3-yl]-1'-isopropyl-4,4'-bipiperidine-1-carboxamide
81A CH CH ethoxy H isopropyl
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-1'-isopropyl-4,4'-bipiperidine-1-carboxamide
81B CH CH ethoxy H isopropyl
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3-
dihydro-1H-indol-3-yl]-1'-isopropyl-4,4'-bipiperidine-1-carboxamide
82 CH CH H H isopropyl
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H-
indol-3-yl]-1'-isopropyl-4,4'-bipiperidine-1-carboxamide 82A CH CH
H H isopropyl
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- indol-3-yl]-1'-isopropyl-4,4'-bipiperidine-1-carboxamide
82B CH CH H H isopropyl
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- indol-3-yl]-1'-isopropyl-4,4'-bipiperidine-1-carboxamide
83 CH CH H methoxy isopropyl
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3-
dihydro-1H-indol-3-yl}-1'-isopropyl-4,4'-bipiperidine-1-carboxamide
83A CH CH H methoxy isopropyl
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-1'-isopropyl-4,4'-bipiperidine-1-carboxamide
83B CH CH H methoxy isopropyl
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3-
dihydro-1H-indol-3-yl}-1'-isopropyl-4,4'-bipiperidine-1-carboxamide
84 CH CH ethoxy methoxy isopropyl
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-1'-isopropyl-4,4'-bipiperidine-1-ca-
rboxamide 84A CH CH ethoxy methoxy isopropyl
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-1'-isopropyl-4,4'-bipiperidine-1-ca-
rboxamide 84B CH CH ethoxy methoxy isopropyl
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2-
oxo-2,3-dihydro-1H-indol-3-yl]-1'-isopropyl-4,4'-bipiperidine-1-carb-
oxamide 85 CH CH methoxy methoxy H
(.+-.)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-
-yl)-2-oxo-
2,3-dihydro-1H-indol-3-yl]-4,4'-bipiperidine-1-carboxamide 85A CH
CH methoxy methoxy H
(+)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo- 2,3-dihydro-1H-indol-3-yl]-4,4'-bipiperidine-1-carboxamide
85B CH CH methoxy methoxy H
(-)-N-[5-cyano-1-[(2,4-dimethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl-
)-2-oxo- 2,3-dihydro-1H-indol-3-yl]-4,4'-bipiperidine-1-carboxamide
86 CH CH methoxy H H
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-
-2-oxo-2,3- dihydro-1H-indol-3-yl}-4,4'-bipiperidine-1-carboxamide
86A CH CH methoxy H H
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3- dihydro-1H-indol-3-yl}-4,4'-bipiperidine-1-carboxamide 86B
CH CH methoxy H H
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(2-methoxyphenyl)sulphonyl]-2--
oxo-2,3- dihydro-1H-indol-3-yl}-4,4'-bipiperidine-1-carboxamide 87
CH CH ethoxy H H
(.+-.)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)--
2-oxo-2,3- dihydro-1H-indol-3-yl]-4,4'-bipiperidine-1-carboxamide
87A CH CH ethoxy H H
(+)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3- dihydro-1H-indol-3-yl]-4,4'-bipiperidine-1-carboxamide 87B
CH CH ethoxy H H
(-)-N-[5-cyano-1-[(2-ethoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-3-yl)-2-o-
xo-2,3- dihydro-1H-indol-3-yl]-4,4'-bipiperidine-1-carboxamide 88
CH CH H H H
(.+-.)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3--
dihydro-1H- indol-3-yl]-4,4'-bipiperidine-1-carboxamide 88A CH CH H
H H
(+)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- indol-3-yl]-4,4'-bipiperidine-1-carboxamide
88B CH CH H H H
(-)-N-[5-cyano-3-(2-ethoxypyridin-3-yl)-2-oxo-1-(phenylsulphonyl)-2,3-dih-
ydro-1H- indol-3-yl]-4,4'-bipiperidine-1-carboxamide 89 CH CH H
methoxy H
(.+-.)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-
-2-oxo-2,3- dihydro-1H-indol-3-yl}-4,4'-bipiperidine-1-carboxamide
89A CH CH H methoxy H
(+)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3- dihydro-1H-indol-3-yl}-4,4'-bipiperidine-1-carboxamide 89B
CH CH H methoxy H
(-)-N-{5-cyano-3-(2-ethoxypyridin-3-yl)-1-[(4-methoxyphenyl)sulphonyl]-2--
oxo-2,3- dihydro-1H-indol-3-yl}-4,4'-bipiperidine-1-carboxamide 90
CH CH ethoxy methoxy H
(.+-.)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyri-
din-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4,4'-bipiperidine-1-carboxamide
90A CH CH ethoxy methoxy H
(+)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-
2-oxo-2,3-dihydro-1H-indol-3-yl]-4,4'-bipiperidine-1-carboxamide
90B CH CH ethoxy methoxy H
(-)-N-[5-cyano-1-[(2-ethoxy-4-methoxyphenyl)sulphonyl]-3-(2-ethoxypyridin-
-3-yl)-2-
oxo-2,3-dihydro-1H-indol-3-yl]-4,4'-bipiperidine-1-carboxamide
[0286] Methods for Determining the Biological Activity
[0287] Vasopressin V1b Receptor Binding Assay:
[0288] Substances:
[0289] The test substances were dissolved in a concentration of
10.sup.-2 M in DMSO and further diluted to 5.times.10.sup.-4 M to
5.times.10.sup.-9 M in DMSO. This series of DMSO predilutions was
diluted 1:10 with assay buffer. The substance concentration was
again diluted 1:5 in the assay mixture (2% DMSO in the
mixture).
[0290] Membrane Preparation:
[0291] CHO-K1 cells with stably expressed human vasopressin V1b
receptor (clone 3H2) were harvested and homogenized in 50 mM
Tris-HCl and in the presence of protease inhibitors (Roche complete
Mini #1836170) with a Polytron homogenizer at a medium setting for
2.times.10 seconds and subsequently centrifuged at 40 000.times.g
for 1 h. The membrane pellet was again homogenized and centrifuged
as described and then taken up in 50 mM Tris-HCl, pH 7.4,
homogenized and stored in aliquots frozen in liquid nitrogen at
-190.degree. C.
[0292] Binding Assay:
[0293] The binding assay was carried out by a method based on that
of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125,
1463-1470 (1998)). The incubation buffer was: 50 mM Tris, 10 mM
MgCl.sub.2, 0.1% BSA, pH 7.4.
[0294] In the assay mixture (250 .mu.l), membranes (50 .mu.g/ml
protein in incubation buffer) from CHO-K1 cells with stably
expressed human V1b receptors (cell line hV1b.sub.--3H2_CHO) were
incubated with 1.5 nM .sup.3H-AVP (8-Arg-vasopressin, PerkinElmer
#18479) in incubation buffer (50 mM Tris, 10 mM MgCl.sub.2, 0.1%
BSA, pH 7.4) (total binding) or additionally with increasing
concentrations of test substance (displacement experiment). The
nonspecific binding was determined with 1 .mu.M AVP (Bachem
#H1780). All determinations were carried out as triplicate
determinations. After incubation (60 minutes at room temperature),
the free radioligand was removed by vacuum filtration (Skatron cell
harvester 7000) through Wathman GF/B glass fibre filter mats, and
the filters were transferred into scintillation vials. The liquid
scintillation measurement took place in a Tricarb model 2000 or
2200CA instrument (Packard). Conversion of the measured cpm into
dpm was carried out with the aid of a standard quench series.
[0295] Evaluation:
[0296] The binding parameters were calculated by nonlinear
regression in SAS. The algorithms of the program operate in analogy
to the LIGAND analysis program (Munson P J and Rodbard D,
Analytical Biochem. 107, 220-239 (1980)). The Kd of .sup.3H-AVP for
the recombinant human V1b receptors is 0.4 nM and was used to
determine the Ki value.
[0297] The test reveals that compounds of the present invention
generally have high affinities towards the V1b receptor which,
expressed as K.sub.i(h-V1b) values, are generally below 150 nM, in
particular at most 50 nM and especially at most 10 nM. The results
are given in table 3
[0298] Vasopressin V1a Receptor Binding Assay:
[0299] Substances:
[0300] The test substances were dissolved in a concentration of
10.sup.-2 M in DMSO. These DMSO solutions were further diluted in
incubation buffer (50 mM Tris, 10 mM MgCl.sub.2, 0.1% BSA, pH
7.4).
[0301] Membrane Preparation:
[0302] CHO-K1 cells with stably expressed human vasopressin V1a
receptor (clone 5) were harvested and homogenized in 50 mM Tris-HCl
and in the presence of protease inhibitors (Roche complete Mini
#1836170) with a Polytron homogenizer at a medium setting for
2.times.10 seconds and subsequently centrifuged at 40 000.times.g
for 1 h. The membrane pellet was again homogenized and centrifuged
as described and then taken up in 50 mM Tris-HCl, pH 7.4,
homogenized and stored in aliquots frozen in liquid nitrogen at
-190.degree. C.
[0303] Binding Assay:
[0304] The binding assay was carried out by a method based on that
of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125,
1463-1470 (1998)).
[0305] The incubation buffer was: 50 mM Tris, 10 mM MgCl.sub.2,
0.1% BSA, pH 7.4.
[0306] In the assay mixture (250 .mu.l), membranes (20 .mu.g/ml
protein in incubation buffer) from CHO-K1 cells with stably
expressed human V1a receptors (cell line hV1a.sub.--5_CHO) were
incubated with 0.04 nM .sup.125I-AVP (8-Arg-vasopressin, NEX 128)
in incubation buffer (50 mM Tris, 10 mM MgCl.sub.2, 0.1% BSA, pH
7.4) (total binding) or additionally with increasing concentrations
of test substance (displacement experiment). The nonspecific
binding was determined with 1 .mu.M AVP (Bachem #H1780). Triplicate
determinations were carried out.
[0307] After incubation (60 minutes at room temperature), the free
radioligand was removed by vacuum filtration (Skatron cell
harvester 7000) through Wathman GF/B glass fibre filter mats, and
the filters were transferred into scintillation vials.
[0308] The liquid scintillation measurement took place in a Tricarb
model 2000 or 2200CA instrument (Packard). Conversion of the
measured cpm into dpm was carried out with the aid of a standard
quench series.
[0309] Evaluation:
[0310] The binding parameters were calculated by nonlinear
regression in SAS. The algorithms of the program operate in analogy
to the LIGAND analysis program (Munson P J and Rodbard D,
Analytical Biochem. 107, 220-239 (1980)). The Kd of .sup.125I-AVP
for the recombinant hV1a receptors was determined in saturation
experiments. A Kd of 1.33 nM was used to determine the Ki
value.
[0311] The test reveals that compounds of the present invention
generally have selectivity towards the V1b receptor in comparison
with V1a receptor, which, expressed as
K.sub.i(h-V1a)/K.sub.i(h-V1b) values generally exceed 10 and are
frequently at least 15, in particular at least 50 and especially at
least 100. The results are given in table 3.
[0312] Vasopressin V2 Receptor Binding Assay:
[0313] Substances:
[0314] The test substances were dissolved in a concentration of
10.sup.-2 M in DMSO. This DMSO solution was further diluted in
incubation buffer (50 mM Tris, 10 mM MgCl.sub.2, 0.1% BSA, pH
7.4).
[0315] Membrane Preparation:
[0316] CHO-K1 cells with stably expressed human vasopressin V2
receptor (clone 23) were harvested and homogenized in 50 mM
Tris-HCl and in the presence of protease inhibitors (Roche complete
Mini #1836170) with a Polytron homogenizer at a medium setting for
2.times.10 seconds and subsequently centrifuged at 40 000.times.g
for 1 h. The membrane pellet was again homogenized and centrifuged
as described and then taken up in 50 mM Tris-HCl, pH 7.4,
homogenized and stored in aliquots frozen in liquid nitrogen at
-190.degree. C.
[0317] Binding Assay:
[0318] The binding assay was carried out by a method based on that
of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125,
1463-1470 (1998)).
[0319] The incubation buffer was: 50 mM Tris, 10 mM MgCl.sub.2,
0.1% BSA, pH 7.4.
[0320] In the assay mixture (250 .mu.l), membranes (50 .mu.g/ml
protein in incubation buffer) from CHO-K1 cells with stably
expressed human V2 receptors (cell line hV2.sub.--23_CHO) were
incubated with 1-2 nM .sup.3H-AVP (8-Arg-vasopressin, PerkinElmer
#18479) in incubation buffer (50 mM Tris, 10 mM MgCl.sub.2, 0.1%
BSA, pH 7.4) (total binding) or additionally with increasing
concentrations of test substance (displacement experiment). The
nonspecific binding was determined with 1 .mu.M AVP (Bachem
#H1780). Triplicate determinations were carried out.
[0321] After incubation (60 minutes at room temperature), the free
radioligand was removed by vacuum filtration (Skatron cell
harvester 7000) through Wathman GF/B glass fibre filter mats, and
the filters were transferred into scintillation vials.
[0322] The liquid scintillation measurement took place in a Tricarb
model 2000 or 2200CA instrument (Packard). Conversion of the
measured cpm into dpm was carried out with the aid of a standard
quench series.
[0323] Evaluation:
[0324] The binding parameters were calculated by nonlinear
regression in SAS. The algorithms of the program operate in analogy
to the LIGAND analysis program (Munson P J and Rodbard D,
Analytical Biochem. 107, 220-239 (1980)). The Kd of .sup.3H-AVP for
the recombinant hV2 receptors is 2.4 nM and was used to determine
the Ki value.
[0325] The test reveals that compounds of the present invention
generally have selectivity towards the V1b receptor in comparison
with V2 receptor, which, expressed as K.sub.i(h-V2)/K.sub.i(h-V1b)
values generally exceed 10 and are frequently at least 15, in
particular at least 25 and especially at least 50.
[0326] Oxytocin Receptor Binding Assay
[0327] Substances:
[0328] The substances were dissolved in a concentration of
10.sup.-2 M in DMSO and diluted with incubation buffer (50 mM Tris,
10 mM MgCl.sub.2, 0.1% BSA, pH 7.4).
[0329] Cell Preparation:
[0330] Confluent HEK-293 cells with transiently expressing
recombinant human oxytocin receptors were centrifuged at
750.times.g and at room temperature for 5 minutes. The residue was
taken up in ice-cold lysis buffer (50 mM Tris-HCl, 10% glycerol, pH
7.4 and Roche Complete Protease Inhibitor) and subjected to an
osmotic shock at 4.degree. C. for 20 minutes. The lyzed cells were
then centrifuged at 750.times.g and at 4.degree. C. for 20 minutes,
the residue was taken up in incubation buffer, and aliquots of
10.sup.7 cells/ml were prepared. The aliquots were frozen at
-80.degree. C. until used.
[0331] Binding Assay:
[0332] On the day of the experiment, the cells were thawed, diluted
with incubation buffer and homogenized using a Multipette Combitip
(Eppendorf, Hamburg). The reaction mixture of 0.250 ml was composed
of 2 to 5.times.10.sup.4 recombinant cells, 3-4 nM .sup.3H-oxytocin
(PerkinElmer, NET 858) in the presence of test substance
(inhibition plot) or only incubation buffer (total binding). The
nonspecific binding was determined with 10.sup.-6 M oxytocin
(Bachem AG, H2510). Determinations in triplicate were set up. Bound
and free radioligand were separated by filtration under vacuum with
Whatman GF/B glass fibre filters using a Skatron cell harvester
7000. The bound radioactivity was determined by liquid
scintillation measurement in a Tricarb beta counter, model 2000 or
2200CA (Packard).
[0333] Evaluation:
[0334] The binding parameters were calculated by nonlinear
regression analysis (SAS), in analogy to the LIGAND program of
Munson and Rodbard (Analytical Biochem 1980; 107: 220-239). The Kd
of .sup.3H-oxytocin for the recombinant hOT receptors is 7.6 nM and
was used to determine the Ki value.
[0335] The test reveals that compounds of the present invention
generally have selectivity towards the V1b receptor in comparison
with Oxytocin receptor, which, expressed as
K.sub.i(h-OT)/K.sub.i(h-V1b) values generally exceed 10 and are
frequently at least 15, in particular at least 25 and especially at
least 50. The results are given in table 3.
TABLE-US-00003 TABLE 3 K.sub.i(h-V1b)* Example [nM]
K.sub.i(h-V1a)/K.sub.i(h-V1b)* K.sub.i(h-OT)/K.sub.i(h-V1b)* 1 +++
+++ +++ 1B +++ +++ +++ 2 ++ +++ +++ 3 ++ +++ +++ 4 ++ ++ ++ 7B +++
+++ +++ 25 +++ +++ ++ 31 +++ +++ +++ 31B +++ +++ +++ 32 ++ + +++ 35
+++ + ++ 37 +++ +++ +++ 37B +++ +++ +++ 40 +++ ++ +++ 40B +++ + +++
43 +++ +++ +++ 55 +++ +++ ++ 61 +++ +++ +++ 61B +++ +++ +++ 67 +++
+++ +++ 67B +++ +++ +++ 85 +++ +++ ++ K.sub.i(h-V1b)
K.sub.i(h-V1a)/K.sub.i(h-V1b) K.sub.i(h-OT)/K.sub.i(h-V1b) +
>50-150 nM 15-50 15-25 ++ 10-50 nM >50-100 >25-50 +++
<10 nM >100 >50
[0336] Determination of the Microsomal Half-Life:
[0337] The metabolic stability of the compounds of the invention
was determined in the following assay.
[0338] The test substances are incubated in a concentration of 0.5
.mu.M as follows:
[0339] 0.5 .mu.M test substance is preincubated together with liver
microsomes of various species (rat, human or other species) (0.25
mg of microsomal protein/ml) in 0.05M potassium phosphate buffer pH
7.4 in microtitre plates at 37.degree. C. for 5 min. The reaction
is started by adding NADPH (1 mg/ml). 50 .mu.l aliquots are taken
after 0, 5, 10, 15, 20 and 30 min, and the reaction is stopped
immediately with the same volume of acetonitrile and cooled down.
The samples are frozen until analyzed. Using MSMS, the remaining
concentration of undegraded test substance is determined. From the
increase of the test substance signal/time unit curve, the
half-life (T1/2) is determined, where the half-life of the test
substance can be calculated, assuming first order kinetics, from
the decrease in the concentration of the compound with time. The
microsomal clearance (mCl) is calculated as mCl=In2/T1/2/(content
of microsomal protein in mg/ml).times.1000[ml/min/mg] (modified
according to the literature references: Di, The Society for
Biomoleculaur Screening, 2003, 453-462; Obach, D M D, 1999 vol 27.
N 11, 1350-1359).
[0340] The test reveals that compounds of the present invention
generally have a high metabolic stability, which result in human
microsomal clearance values of generally at most 220 .mu.l
min.sup.-1 mg.sup.-1, frequently 120 .mu.l min.sup.-1 mg.sup.-1 and
in particular at most 60 .mu.l min.sup.-1 mg.sup.-1. The results
are given in table 4.
TABLE-US-00004 TABLE 4 Human Mikrosomal Clearance Example [.mu.l
min.sup.-1 mg.sup.-1] 1 +++ 1B +++ 4 +++ 5 +++ 7B +++ 25 +++ 31 ++
31B +++ 34 +++ 35 ++ 37 ++ 37B +++ 40 ++ 40B ++ 55 ++ 61B +++ 85 ++
Human Mikrosomal Clearance + >120-220 .mu.l min.sup.-1 mg.sup.-1
++ 60-120 .mu.l min.sup.-1 mg.sup.-1 +++ <60 .mu.l min.sup.-1
mg.sup.-1
[0341] Determination of Plasma Protein Binding (PPB) by Equilibrium
Dialysis:
[0342] 150 .mu.l of rat or human plasma, with 1 or 10 .mu.M of test
substance added, is pipetted onto one side of the 96-well dialysis
chambers, 150 .mu.l of PPS buffer are pipetted onto the other side.
The chambers are separated by a dialysis membrane having a cut-off
of 6-8000 dalton.
[0343] The 96-well dialysis chambers are covered and gently shaken
overnight.
[0344] The next morning, 10 .mu.l of plasma are removed and diluted
with 90 .mu.l of PPS buffer, and the protein is precipitated using
200 .mu.l of acetonitrile. The precipitated protein is removed by
centrifugation, and 100 .mu.l of the supernatant are used for MSMS
analysis. From the buffer side, 100 .mu.l are removed for MSMS
analysis. See also the following literature reference: Banker,
Journal of Pharmaceutical Sciences Vol. 92, 5, 967-974, 2003.
[0345] Methods for the In Vitro Determination of Cytochrom P450
(CYP) Inhibition
[0346] Luminescence Substrates for 2C9 and 3A4:
[0347] 0.4 mg/ml of human liver microsomes are preincubated for 10
minutes with the test substances to be tested (0-20 .mu.M), the CYP
specific substrates, in 0.05 M potassium phosphate buffer pH 7.4 at
37.degree. C. The Cyp-specific substrate for CYP 2C9 is luciferin
H, that for CYP 3A4 is luciferin BE. The reaction is started by
addition of NADPH. After 30 min of incubation at RT, the luciferin
detection reagent is added, and the resulting luminescence signal
is measured (modified according to literature reference: Promega,
Technical Bulletin P450-GLO.TM. Assays).
[0348] Midazolam CYP 3A4 Time-Dependent Inhibition
[0349] The test consists of 2 parts. In the first part, the test
substance is preincubated with the liver microsomes (with
NADPH)=preincubation, followed by addition of the substrate; in the
second part, substrate and test substance are added
simultaneously=coincubation.
[0350] Preincubation:
[0351] 0.05 mg/ml of microsomal protein (human liver microsomes)
are preincubated with 0-10 .mu.M (or 50 .mu.M) of test substance in
50 mM potassium phosphate buffer for 5 min. The reaction is started
using NADPH. After 30 min, 4 .mu.M of midazolam (final
concentration) are added, and the mixture is incubated for a
further 10 min. After 10 min, 75 .mu.l of the reaction solution are
removed and quenched with 150 .mu.l of acetonitrile solution.
[0352] Coincubation:
[0353] 0.05 mg/ml of microsomal protein (human liver microsomes), 4
.mu.M midazolam (final concentration) and 0-10 .mu.M (or 50 .mu.M)
of test substance are preincubated in 50 mM potassium phosphate
buffer for 5 min. The reaction is started using NADPH. After 10
min, 75 .mu.l of the reaction solution are removed and quenched
with 150 .mu.l of acetonitrile solution. The samples are frozen
until analyzed by MSMS (modified according to literature
references:
[0354] Obdach, Journal of Pharmacology & Experimental
Therapeutics, Vol 316, 1, 336-348, 2006; Walsky, Drug Metabolism
and Disposition Vol 32, 6, 647-660, 2004).
[0355] Method for Determining the Solubility in Water (in
mg/ml)
[0356] The solubility in water of the compounds according to the
invention can be determined, for example, according to the
so-called "shake flask" method (according to ASTM International: E
1148-02, Standard test methods for measurement of aqueous
solubility, Book of Standards Volume 11.05.). Here, an excess of
the solid compound is added to a buffer solution having a certain
pH (for example phosphate buffer pH 7.4) and the resulting mixture
is shaken or stirred until the steady state has been reached
(typically 24 or 48 hours, sometimes even up to 7 days). The
undissolved solid is then removed by filtration or centrifugation,
and the concentration of the dissolved compound is determined by UV
spectroscopy or high-pressure liquid chromatography (HPLC) using an
appropriate calibration curve.
* * * * *